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TARGETING AN ANCIENT RETROVIRUS DURING MELANOMA USING 
ADOPTIVE T CELLS THERAPY 
Janani Krishnamurthy, B.Pharm, M.S. 
Supervisory Professor: Laurence J.N. Cooper, Ph.D., M.D. 
Patients with metastatic melanoma have a poor prognosis due to resistance to conventional 
therapies. Thus, new targeted treatment strategies are required to improve therapeutic 
outcome. One prospective approach is to infuse T cells that are rendered specific for tumor-
associated antigens (TAAs) preferentially expressed on melanoma cells. Recognition of cell-
surface TAAs independent of major histocompatibility complex can be achieved by 
introducing a TAA-specific chimeric antigen receptor (CAR) on T cells using gene therapy. 
This approach is being used in clinical trials to adoptively transfer CD19-specific CAR+ T 
cells in patients with B-lineage malignancies. To generate T-cell therapy for melanoma we 
targeted a TAA derived from human endogenous retroviruses (HERV), whose genome 
stably integrated into humans millions of years ago. During oncogenesis, biologically active 
variants of HERV, such as the envelope (env) protein of HERV-K, are expressed on the 
surface of melanoma, but not normal cells. To target HERV-K, T cells were engineered to 
express a CAR specific for this env protein, by replacing the antigen-binding exodomain of 
CD19-specific CAR with the single chain antibody (scFv) sequence of an anti-HERV-K env 
specific monoclonal antibody. This new CAR was cloned as a transposon into our Sleeping 
Beauty (SB) system that we have adapted for human application. DNA plasmids coding for 
the HERV-K env-specific CAR and SB transposase were electro-transferred into primary 
ix 
human T cells, and genetically modified CAR+ T cells were selectively propagated on 
irradiated artificial activating and propagating cells (AaPC) expressing HERV-K env and the 
desired T-cell co-stimulatory molecules. After co-culture on γ-irradiated AaPC, 95% of 
CD3+ T cells expressed the CAR and these HERV-K env-specific CAR+ T cells were able to 
specifically kill HERV-K env+, but not HERV-K env-, melanoma targets in vitro in contrast 
to control (no DNA) T cells. Specificity of these CAR+ T cells was proved by over- 
expressing HERV-K env protein in antigen negative EL4 mouse cells that were 
preferentially killed compared to HERV-K env- EL4 parental cells. HERV-K env  
knockdown by shRNA on A888 cells resulted in reduced killing compared to parental A888 
melanoma cells. A novel observation was that the antigen is not a type 1 transmembrane 
protein and that it is shed from its surface which is recognized by HERV-K env-specific 
CAR+ T cells.  The CAR+ T cells were also successful in reducing tumor growth and 
metastasis of A375-super metastatic (SM) tumor cells from lungs to liver in vivo. The tumor-
bearing mice receiving the CAR+T cells lived longer and appeared healthier than the control 
tumor-bearing mice who received no CAR+ T cells. In aggregate, these data demonstrate for 
the first time that T cells targeting an active ancient retrovirus can be used as an 
immunotherapy for melanoma, using an approach that has translational appeal for clinical 
trials. 
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Chapter 1:  Introduction 
1.1 Melanoma: Melanoma, a cancer of melanocytes, which are melanin pigment-producing 
cells in the skin, is the most serious form of skin cancer. The incidence of melanoma has 
increased over the years faster than other cancers 1. It is the second and third most commonly 
diagnosed cancer in women and men respectively. In the USA, nearly 55,560 individuals 
were diagnosed with melanoma in the year 2012 alone with the incidence rate of melanoma 
steadily rising over the last 30 years 2,3. In the United States, there is a 1 in 30 chance in risk 
of developing melanoma 4. Though the median age of diagnosis for male and female has 
been 60 years, recently more patients under 30 years are being diagnosed with melanoma.  
20% of all primary melanoma lesions will metastasize depending upon the primary tumor 
size, age, gender, anatomical sites, infiltration of lymphocytes and ulceration 3. One of the 
most aggressive forms of skin cancer is metastatic melanoma and accounts for up to 46,000 
deaths annually worldwide 1.  
The National Cancer Institute describes the different stages of melanoma as follows: Stage 0 
or melanoma in situ includes abnormal melanocytes found on the epidermal layer of the 
skin.  These melanocytes have a propensity to become cancerous and spread; Stage I: the 
tumor is about 1-2 millimeter thick with or without ulceration; Stage II: the tumor is 2-4 
millimeter thick with or without ulceration; Stage III: the primary tumor can be any 
thickness with or without ulceration but has spread to lymph nodes and smaller tumors are 
found approximately 2 centimeters from the primary site; Stage IV: the cancer has 
metastasized to other organs such as the lung, liver, gastrointestinal tract, bone and other soft 
tissues.  
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The survival of patients diagnosed at various stages of disease progression drops from 95% 
at stage I to 10% at stage IV. Treatment of melanoma is dependent on the stage of disease 
progression. Routine therapy for stage 1 and 2 melanoma includes surgical excision. About 
half the patient population with advanced disease receives either chemotherapy or 
immunotherapy along with radiation and surgery.  Adjuvant therapy such as Interferon-α 
(IFN-α) is administered to patients with increased risk of disease recurrence 5,6. Until 2011, 
the only two US FDA approved therapies for metastatic melanoma were chemotherapy with 
dacarbazine and high-dose IL-2 7,8. Widespread multiorgan toxicity was reported with high-
dose IL-2 and low response rates of about 10-15% were reported with dacarbazine 9-11. 
Newer therapeutic interventions such as ipilimumab, which targets cytotoxic T-lymphocyte-
associated antigen 4 (CTLA-4) and vemurafenib, a BRAF inhibitor are now FDA-approved 
after showing efficacy in clinical studies targeting metastatic melanoma 12-14.  
 
Despite the development of these therapeutic options, the incidence and frequency of 
complete or partial regression of melanoma has not improved over the years 15. Melanoma 
with micrometastases to secondary sites is in general not a candidate for treatment due to 
three factors namely (a) inadequate detection using current tomographic procedures 16,17 (b) 
persistence of micrometastases in a dormant stage 18 and, (c) resistance of micrometastases 
to chemo- and radiation therapy 19-21. 
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1.2 Immune landscape in the melanoma microenvironment 
Previous clinical studies on tumor environment of melanoma strongly suggest that the 
immune system can be naturally harnessed to target and clear melanoma cells 22. In primary 
melanoma, about 14-50% of the tumor spontaneously disappears without treatment. It has 
been suggested this is due to the robust activity and infiltration of CD4+ and CD8+ T cells at 
the tumor site 23. Thus, immune-based targeted therapy where the immune cells are 
manipulated to enhance its response can be a potential therapy for overcoming the toxicity 
and low response rate associated with the current treatment protocols for metastatic 
melanoma. Melanoma cells that express tumor-associated antigen (TAA) can be recognized 
by antigen-specific autologous antibody and T cells resulting in a targeted tumor clearance. 
TAAs on melanoma cells were categorized as 24-28  
• Differentiation antigens – expressed on malignant and normal malanocytes - gp100, 
tyrosinase, melan-A and the retained intron in tyrosinase-related protein (TRP-2-
INT2)  
• Cancer testis antigens – expressed on malignant tumor and not on normal tissues 
(except testis and placenta) - melanoma antigen 1 (MAGE1), Ny-ESO-1, PRAME, 
mutated CDK4 and MUM1. 
The above mentioned TAAs can be used as potential targets for immunotherapies.  
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Figure. 1: Melanoma as a model tumor for immuno-oncology. Adopted from reference with 
permission from Maio M 2012. Melanoma as a model tumour for immuno-oncology. Ann 
Oncol  23 Suppl 8:viii10-14. 
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1.3 Immunotherapy for melanoma: Before 2011, the treatment strategy for metastatic 
melanoma included chemotherapy and IL-2. Over the years, many immune therapies have 
been tested against melanoma. These therapies fall in three different strategies: 
• Therapeutic vaccination includes anti-idiotypic (anti-Id) antibodies as “surrogate” 
TAA to induce or potentiate a systemic TAA-specific immune response 
• Passive immunization where antibodies or their derived molecules directly target 
tumor-associated antigens (TAA) expressed on malignant cells. 
• Adoptive T cell therapy includes transfusion of autologous or allogeneic T cells to 
control tumor growth in patients. This therapy is based on the inherent cytolytic 
activity of T cells in killing tumor cells. The strategies for adoptive T cell therapy 
include tumor infiltrating lymphocytes (TILs) and Engineered T cells   
Many immune therapies have been tested against melanoma with varying results. There are 
two broad classifications of immune therapy: specific and non specific (Figure. 1). Non-
specific immunotherapy which includes infusion of large doses of IL-2 and IFN-a2b or 
allogenic bone marrow transplant involve toxicity associated with dosage and restriction in 
the population of patient eligible for such therapy29. In contrast, specific immunotherapy 
which includes antibody and T cell- derived therapy are lesser off-target toxicity compared 
to non-specific treatment options.  
 
Monoclonal antibody based therapy for melanoma: 
The generation of the first murine monoclonal antibody was possible with the development 
of hybridoma technology and mice breeding. In the 1980s a range of antibodies were 
6 
introduced in clinical trials for the treatment of various solid tumors 30. The development of 
toxicity to these murine antibodies accelerated the production of engineered humanized 
monoclonal antibody which revolutionized cancer treatment strategy 31. For melanoma 
treatment, the development of a clinically relevant antibody-based therapeutic approach has 
been the focus of interest for considerable time. Treatment of melanoma with anti-GD3 
murine R24 monoclonal antibody alone or in combination with chemotherapy showed poor 
clinical response 32. Therapeutic vaccination with a melanoma associated TAA resulting in 
production of idiotypic (Id) antibody was also explored 33.   
 
T cell therapy: 
In the past decade adoptive T cell therapy (ACT) has emerged as an optimistic therapeutic 
strategy for tumor elimination. ACT involves isolation and ex vivo expansion of autologous 
T cells in an antigen non-specific manner. These expanded T cells are later infused into the 
patient and have been shown to result in successful regression of melanoma 34.   
 
Tumor infiltrating lymphocytes (TILs) 
Melanoma is considered a highly immunogenic tumor due to the presence of TILs at the 
tumor site 35. The concept of TILs has evolved from a cancer inducing immune cell to cancer 
ablating immune cells 35,36.  In the early days, TILs also served as a prognostic marker, with 
an increase in lymphocyte infiltration predicting improved prognosis of 3-5 years in patients 
with metastatic melanoma 37. These TILs can recognize melanoma associated tumor antigen 
and lyse tumor cells in a major histocompatibility complex (MHC) dependent manner 38. 
TILs are isolated from the tumor site and pulsed with melanoma specific peptides along with  
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antigen presenting cells, such as dendritic cells, with the addition of IL-2,  resulting in 
several fold expansion of TILs ex vivo 39,40. Though TIL therapy has successfully reduced 
melanoma progression, the effectiveness of the therapy may be reduced due to several 
reasons including (i) TILs sometimes include exhausted and/or senescent functionally 
anergic memory T cells 41 (ii) though the peptides used for the ex vivo expansion of TILs 
have anchor residue for HLA molecules, they might not elicit the expansion of tumor-
specific T cells 42., e.g. in a panel of 10 MART-1 peptides used only one successfully 
induced the TILs for melanoma recognition 43 (iii) as melanoma progresses, the tumor cells 
modulate the expression of TAA on their surface and alter their phenotype in a process 
known as immunosculpting, which enables avoidance of immuno-surveillance by the host 
immune system and leads to failed spontaneous or therapy-induced regression of metastatic 
tumor 44,45. To circumvent these shortcomings, there is a need to develop engineered T cell 
therapy that can recognize tumor targets and bring about active tumor regression.  
 
Engineered T cell therapy: 
There are two approaches for engineering re-directed T cell specificity (Figure. 2) 46: 
1. Gene modification with tumor specific T-cell receptors (TCRs) in which the α and β  
chains of the TCR are cloned from TAA-specific T cell clones.  
2. Introduction of chimeric antigen receptor (CAR) that recognizes TAAs through the single 
chain variable region (scFv) that is derived from the corresponding monoclonal antibody. 
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Figure. 2:  Schematic representation of patients receiving T cells with T-cell receptor (TCR) 
or chimeric antigen receptor (CAR) T cells. (1) Patient peripheral blood T cells isolation. (2) 
T cells are engineered to express antigen-specific TCR or CAR genes (3) Expansion and 
adoptive transfer of antigen-specific T cells with prior lymphodepleting conditioning. 
Adopted from reference with permission from Shi H, Liu L, Wang Z 2013. Improving the 
efficacy and safety of engineered T cell therapy for cancer. Cancer Lett  328(2):191-197. 
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TCR-based therapy: 
TCRs are found on the T cell surface as heterodimers of α and β chain that are rendered 
specific to an antigen presented by MHC on an antigen presenting cells (APC). Genes of 
tumor antigen specific TCR are isolated from patients and engineered into T cells using a 
viral or non-viral based vector system 47,48. These T cells are expanded ex vivo to generate 
large numbers for infusion. Improvements in vector design, avidity of TCR by amino acid 
substitution in its complementarity determining region (CDR3)  and introduction of 
cysteines to form disulphide bonds thereby preventing α and β chain mispairs has increased 
the efficacy of this therapy 49-51 52.   
Though the TCR driven ACT is effective in reducing tumor 53, increased incidence of 
toxicity was reported especially with high avidity TCRs 54. Patients with epithelial cancer 
infused with T cells bearing TCR specific to carcinoembryonic antigen (CEA) developed 
inflammatory colitis 54. Also TCR specific therapy is MHC restricted hence tumor cells can 
lose antigen expression by down regulating MHC thereby evading the T cells 55. Hence the 
application of TCR-specific T cell recognition is restricted to a single type of MHC molecule 
presenting the antigen 56. In order to circumvent this problem CAR-based therapy was 
developed where the tumor recognition of the TCR will be non-MHC dependent 57,58.  
 
CAR based therapy:  
The CAR based therapy involves genetically engineered fusion of variable light (VL) and 
variable heavy chain (VH) specific for the antigen with a cell surface molecule which is 
tailored to produce an activating signal to the host immune cell upon antigen engagement 59. 
These CARs are generally delivered to the peripheral blood T cells using a mammalian-
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based Sleeping Beauty (SB) vector or nonmammalian-based retroviral system. The CAR 
identifies the tumor target in a human leukocyte antigen (HLA) independent manner unlike 
the αβ TCR receptors. Key advantages of this therapy include 
- CAR based approach can be used in all tumor conditions expressing the antigen 
and is not MHC restricted. 
- varied range of tumor antigens can be targeted using this system including 
glycoproteins and lipids 60-62.  
The overall structure of the CAR consists of four elements namely the antigen targeting 
domain, an extracellular linker/spacer, a membrane spanning domain and intracellular 
signaling domain. The CAR has gone through successive generations with fine structural 
refinement (Figure. 3) 63. The antigen specific domain is generally derived from the scFv 
portion of the monoclonal antibody (mAb) targeting the antigen. The linker is required to 
make the CAR flexible to reach the antigen. A mutated IgG derived Fc sequence that does 
not activate the innate immune cells is commonly used due to its stability in expressing the 
CAR on cell surface 64. The transmembrane transitioned from CD4 or CD8 (first generation 
CARs) to CD28 (second generation CARS) 65. The signaling endodomain of second 
generation CARs had CD3ζ along with the co-stimulatory signaling domain CD28 66. 
Improved tumor clearance and persistence has been observed in second and third generation 
CAR+ T cells compare to the first generation CARs 64-70.   
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Figure. 3: Schematic representation of first (1G), second (2G) and third (3G) generation 
CAR molecules. Adopted from reference  with permission from Casucci M, Bondanza A 
2011. Suicide gene therapy to increase the safety of chimeric antigen receptor-redirected T 
lymphocytes. J Cancer  2:378-382. 
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Introduction of CAR into T cells:  
Multiple vector systems have been developed to introduce the CAR into T cells. Of these, 
mammalian transposon/transposase based vectors can produce robust integration with low 
immunogenicity and more ease for plasmid manipulation 71. Multiple mammalian vectors 
have been studied including Sleeping Beauty (SB) transposon (derived from fish Tanichthys 
albonubes), piggyBac element (moth Trichoplusia ni), Frog Prince (frog Rana 
pipiens), Himar1 (hornfly Haematobia irritans), Tol2 (fish Oryzias latipes), 
and Passport (flatfish Pleuronectes platessa) 72. Among all element with activity in 
mammalian cell, SB transposon is one of the most widely studied for gene-transfer purpose 
73
. A typical SB vector consists of the target gene sequence flanked by 230 bps long inverted 
and direct repeats (IR/DR) 73. These IR/DR sites are involved in binding with SB transposase 
to transfer the target gene to host genome. The SB transposase was derived by combining 
inactive transposase sequences from the genome of salmonid fish followed by reversing 
termination codon to activate the transposase activity 71. Components of SB transposase 
include IR/DR sequence, DNA recognition site, nuclear localization signal (NLS) and 
catalytic domain.  
Gene transfer using SB transposon/transposase involves cut and paste mechanism 74. The SB 
transposase protein is translated and accumulated in the cytoplasm which is then imported 
into the nucleus using NLS. The SB transposase protein binds to the IR/DR sequence of the 
transposon causing DNA breaks flanking the gene of interest.  
Integration site of gene cut from the SB transposon into the T cell genome depend on the 
presence of dinucleotide TA site, DNA flexibility and proximity of the donor and receiver 
(local hopping) 75-77. More than 25% of integrations happen within 200 bp between the donor 
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and receiver sites of the gene and more than 75% of integration happen in a single 
chromosome.   
 
1.4 CAR based immune therapy for melanoma  
Despite the success of CAR T cell therapy in treating patients with conditions including 
chronic and acute myeloid leukemia (CML, AML) and colon cancer, there are no successful 
clinical studies using CAR T cell therapy for melanoma 78. Pre-clinical studies on mouse 
models such as SCID and NOG using CARs specific for melanoma antigens such as GD2, 
GD3 and MAGE-A1 have suggested the feasibility of this therapy in the clinic 60,79,80.   
One of the major concerns of CAR therapy is the toxicity profile. These CAR+T cells are 
highly specific to the tumor associated antigen which can also be expressed on normal cells. 
A clinical study on patients with metastatic colon cancer using CAR specific against ERBB2 
tumor antigen resulted in respiratory distress within fifteen minutes of infusion due to influx 
of infiltrates into the lungs 81.  
Hence in summary, CAR T cell therapy can be a potential strategy to bring about immune 
cell mediated tumor antigen recognition, generate memory lymphocytes and prevent immune 
suppression 82. Toxicity issues during available immunotherapy necessitate the need to 
identify new antigens that are specifically expressed on metastatic melanoma cells and not 
on normal tissue.   
1.5 Oncogenesis of retrovirus: 
An estimated one in five cancers is associated with viral infection83. The discovery of 
retrovirus involvement in cancer involved the transformation of tumor free chicken cell to 
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acquire erythro myeloblastic leukemia in 1908.  The factor involved in this transformation 
was later identified as avian myeloblastosis virus 83. Later research in mice led to the 
discovery of mouse mammary tumor virus 84. Discovery and invention of quantitative focus 
forming assays, and of reverse transcriptase, helped in further understanding the mechanism 
of tumorigenesis of these viruses 85,86. Several biomolecular studies were performed to 
illustrate the mechanism of oncogene activation leading to pathogen-induced/related cancer. 
These include (a) introduction of exogenic viral oncogenes (b) activation of endogenous 
retrovirus (c) inactivation of suppressor genes 87. 
Oncogenic retroviruses are classified into two subgroups depending on their pathogeneses. 
The first group, the acute transforming retroviruses, are defective in replicating and induce 
cancer via their viral oncogenes. The second group, the non-acute retroviruses, are 
competent in replication but are devoid of oncogenes and they cause cancer by inserting the 
proviral DNA around the genes encoding proto-oncogenes 88.  
A retrovirus typically consists of a single-stranded RNA genome ranging from 7 to 13 kb. 
This genome encodes the structural proteins gag, pro, pol and env (Figure. 4). In addition to 
this, a wide array of accessory proteins such as viral capsid proteins, viral proteases, viral 
enzymes (reverse transcriptase and integrase) are encoded. Retroviral infection involves 
formation of provirus by cleaving the gal-pro-pol polyprotein precursor. The viral RNA is 
reverse transcribed (RT) into viral DNA in the host cell. The RT-viral DNA consists of long 
terminal repeats (LTR) which are classified into three regions, U3, R and U5 regions, based 
on their functionality. The U3 LTR which includes the promoter and enhancer sequence is 
responsible for initiation of transcription. The U3-R region involves the transcription of 
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provirus by RNA polymerase II, and the RNA cleavage and polyadenylation occurs at the R-
U5 downstream region 88. 
In general retroviruses target the somatic cells for their ability to replicate and do not lyse the 
target cells resulting in a long term association of the somatic cell with the virus. However, 
when these retroviruses target the gamete cells the provirus becomes permanently embedded 
in the host genome and passed on through successive generations during the course of 
evolution. These inherited provirus are termed “endogenous retroviruses” and some these 
elements have been recorded in fossils dating back 40 million years 89. Phylogenetic analysis 
reveals that there are about 31 groups of ERV variants integrated into the human genome 90. 
These ERVs typically consists of 2LTRS separated by approximately 300 to 1000 
nucleotides in length that encode for the structural proteins of the virus 91. The chromosomal 
location of each ERV is unique due to random integrations 89. Though the ERVs initially 
colonized the human germline, over the period of time the ERV coding sequence 
accumulated a multitude of random mutations making them noninfectious to the host cells 92.   
Alternatively the ERV transcription is silenced in differentiated tissues by epigenetic 
silencing such as DNA methylation, histone modifications and RNA interference 93,94. 
The present method of classification of HERVs is based on the first letter amino acid code 
involved in t-RNA complimentary to the primer binding site used for reverse transcription. 
Thus HERV-K has lysine as the starting amino acid in its tRNA primer 95. This classification 
however, does not take into account the fact that the different pro-viruses can have the same 
primer binding site sequence. The frequency of ERV integration in various species has been 
helpful in indicating the evolutionary significance. 
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Figure. 4: Schematic structure of a retrovirus. Adopted from reference with permission from 
Dr. Rycaj. 
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In silico analysis has shown evidence for relative distribution of LTR elements in the host 
genome are generally found in the intergenic regions than the introns and are generally 
underrepresented 96,97. The LTR sequences found in the introns are generally in the opposite 
transcriptional orientation from that of the host gene emphasizing the deleterious effect of 
viral gene expression 97. 
The provirus content in humans exhibits reduced polymorphism compared to other mammals 
since most of the proviral element locations are the same as in chimpanzees. In contrast to 
this observation is the active member of HERV, mouse mammary tumor virus (MMTV) 
related HERV-K (HML-2), which was discovered only in the humans 98. 
 
1.6 Evolutionary significance of HERVs: 
 Immunity: When a retrovirus is endogenously integrated with the germ cell of a species its 
expression may interfere with other exogenous retroviruses infecting the host. This might 
provide a selective advantage in the survival and propagation of the host causing extinction 
of the exogenous counterpart (Figure. 5) 99. Transmission of the virus within and between 
species may alter the pathogenicity and virulence of the virus. HERV-W has been shown to 
protect the host from superinfection  by exogenous retrovirus in vitro 100.  
Development: In addition to providing protection against exogenous infections, some ERVs 
have been adapted in the host genome to provide additional physiological advantages. One 
such example is the HERV-W and HERV-FRD mediated syncytins-1 and syncytin-2 
proteins that are involved in the   placental membrane development by protein cell fusion 
and syncytium formation 101. Syncytin-2 is also known to be involved in immune 
suppression which may be involved in protecting the fetus from host rejection or cancer 
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progression in humans 102,103.  The env protein of HERV-R is found to be expressed in 
several fetal tissues including the adrenal gland and is suggested to contribute to cellular 
differentiation and placental development 104.  
Promoters: The function of a genome can be altered by the retroviral sequence integrated 
nearby to the corresponding gene 91. Retroviral LTRs are in general found in antisense 
direction upstream and in sense direction downstream to a host gene 84. For example, 
integration of HERV-E LTR in antisense direction upstream of the amylase gene promotes 
its expression from the parathyroid glad and its release into saliva 105.  Strong bidirectional 
promoter activity has been observed with several LTRs of HERV-H group 106. HERV-E 
LTRs are involved in promoting the transcription of apolipoprotein C-1 which in turn 
regulates other genes in the genome 107.  
Regulatory elements and anti-cancer properties: About 30% of all p53 binding sites are 
HERV LTR sequence and regulate the expression of p53 genome-wide contributing to the 
anti-oncogenic functions 108.  Renal cancer cells with increased protein expression of HERV-
E were shown to recruit T-cells from allogeneic transplant donors and led to tumor 
regression in patients undergoing immunotherapy suggesting the HERVs are dormant and 
re-activation is not well tolerated by the host cells 109. 
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Figure. 5: Schematic representation of transmission of HERV-K virus between species and 
persistent survival of species due to presence of viral genes in their genome. Adopted from 
reference with permission from Jern P, Coffin JM 2008. Effects of retroviruses on host 
genome function. Annu Rev Genet  42:709-732. 
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1.7 HERV-K  
Among all the HERVs studied, HERV-K is one the youngest and the most active provirus 
found in the host genome 110. One such example is HERV-K 113 located on chromosome 19 
and possesses all open reading frames for genes encoding Gag, Pol, Env and a protease 
flanked by two non-coding LTRs. Apart from these structural proteins, two accessory 
proteins Rec and Np9 proteins are also encoded specific to the HERV-K family 111. Rec 
protein is responsible for nuclear transport of spliced mRNA into the cytoplasm and Np9 is 
known to be involved in transcriptional regulation of myc- related proto oncogenes 112,113.  
The Rec and Np9 protein is suggested to be involved in pro-oncogenesis by increased levels 
of myc and its downstream products such as p53 resulting in reduced apoptosis and 
increased proliferation 113,114.   
Non-allelic homologous recombination (NAHR) of different isoforms of HERV-K at the 
same or a different chromosomal location can lead to human genomic rearrangement. In 
about 40 haploid copies of HERV-K, one-tenth of these subfamily members have undergone 
NAHR after insertion into the human genome 115.  Though most of the HERVs deposited in 
the human genome are silent, they can be activated by external or internal triggers such as 
environmental factors including diet, infection from exogenous virus or cancer 116-119. For 
instance, Epstein-Barr virus (EBV) infection mediated interferon-gamma (IFN-γ) production 
by host T cells leads to transcriptional activation of HERV-K18 at the CD48 locus 120.  
Transcriptional activation of HERV-K has been attributed to the epigenetic changes which 
include CpG methylation of the U3 promoter sequence 121. Low level of LTR methylation 
results in increased levels of HERV-K 122.  Apart from methylation, APOBEC3G-mediated 
cytidine deamination is also involved in suppressing HERV-K LTR activation 123.  
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Apart from epigenetic changes, transcriptional regulators also play an important role in 
regulating HERV-K expression. Ubiquitous regulators belonging to the family of SP, YY1, 
microphthalmia-associated transcription factor (MITF-M) proteins which are implicated in 
various pathologies such as cancer are suggested to bind to the GC region (G rich elements), 
5’terminus of the U3 promoter of HERV-K proviral LTR and the U3 region of HERV-K6 
124-126
. Indirect activation of HERV-K has been observed by alternative transcriptional 
regulators such as OCT-1 and bZip family members (AP-1 and CREB) during exogenous 
infection 127-129. HERV-K has several NF-κB binding sites which results in upregulation of 
the proviral expression during inflammation mediated by IFN-γ 130-132, TNF-α 133 or IL-6 134 
which mediate increased NF-κB production thereby inducing HERV-K 135. Recent HERV 
genome sequencing has shown that 0.2 to 1% of all cell transcription factors in a cell are 
derived from HERVs and some have tissue specific transcription activity 136.  
 
1.8 HERV-K involvement in human diseases 
Among the HERV family, HERV-K is the only member found to have intact open reading 
frames and produce retroviral particles 111,137,138. HERVs are suggested to play a role in 
tumor development by their immune suppressor function involved in fetal development 
which can be detrimental for the host during tumor growth (Table. 1) 138,139. Antibodies 
against the transmembrane portion of HERV-K have been detected in the serum of some 
tumor patients and pregnant women 140. The transmembrane proteins of many HERV env 
proteins have been shown to contribute to this immune suppressor function 103,141.   
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Table. 1: 
 
 
HERV-K 
expressing tumor 
and infections 
Reference 
Melanoma 1. Muster T, Waltenberger A, Grassauer A, et al. An endogenous retrovirus derived 
from human melanoma cells. Cancer Res. Dec 15 2003;63(24):8735-8741. 
 2. Buscher K, Trefzer U, Hofmann M, Sterry W, Kurth R, Denner J. Expression of 
human endogenous retrovirus K in melanomas and melanoma cell lines. Cancer Res. 
May 15 2005;65(10):4172-4180 
 3. Li Z, Sheng T, Wan X, Liu T, Wu H, Dong J. Expression of HERV-K correlates 
with status of MEK-ERK and p16INK4A-CDK4 pathways in melanoma cells. 
Cancer Invest. Dec 2010;28(10):1031-1037. 
 4. Reiche J, Pauli G, Ellerbrok H. Differential expression of human endogenous 
retrovirus K transcripts in primary human melanocytes and melanoma cell lines after 
UV irradiation. Melanoma Res. Oct 2010;20(5):435-440. 
 5. Serafino A, Balestrieri E, Pierimarchi P, et al. The activation of human endogenous 
retrovirus K (HERV-K) is implicated in melanoma cell malignant transformation. 
Exp Cell Res. Mar 10 2009;315(5):849-862 
Breast cancer  1. Patience C, Simpson GR, Colletta AA, Welch HM, Weiss RA, Boyd MT. Human 
endogenous retrovirus expression and reverse transcriptase activity in the T47D 
mammary carcinoma cell line. J Virol. Apr 1996;70(4):2654-2657 
 2. Wang-Johanning F, Frost AR, Jian B, Epp L, Lu DW, Johanning GL. Quantitation 
of HERV-K env gene expression and splicing in human breast cancer. Oncogene. 
Mar 13 2003;22(10):1528-1535. 
 3. Seifarth W,  Skladny H,  Krieg-Schneider F, Reichert A,  Hehlmann R, Leib-
MoschC. Retrovirus-like particles released from the human breast cancer cell line 
T47-D display type B- and C-related endogenous retroviral sequences. J 
Virol.1995;69(10):6408-6416. 
Ovarian Cancer Wang-Johanning F, Liu J, Rycaj K, et al. Expression of multiple human endogenous 
retrovirus surface envelope proteins in ovarian cancer. Int J Cancer. Jan 1 
2007;120(1):81-90 
Lymphoma Contreras-Galindo R, Kaplan MH, Leissner P, et al. Human endogenous retrovirus K 
(HML-2) elements in the plasma of people with lymphoma and breast cancer. J Virol. 
Oct 2008;82(19):9329-9336. 
Teratocarcinoma 1. Bieda K, Hoffmann A, Boller K. Phenotypic heterogeneity of human endogenous 
retrovirus particles produced by teratocarcinoma cell lines. J Gen Virol. Mar 
2001;82(Pt 3):591-596. 
2. Lower R, Lower J, Tondera-Koch C, Kurth R. A general method for the 
identification of transcribed retrovirus sequences (R-U5 PCR) reveals the expression 
of the human endogenous retrovirus loci HERV-H and HERV-K in teratocarcinoma 
cells. Virology. Feb 1993;192(2):501-511. 
Acquired 
immunodeficiency 
syndrome (AIDS) 
Jones RB, Garrison KE, Mujib S, et al. HERV-K-specific T cells eliminate diverse 
HIV-1/2 and SIV primary isolates. J Clin Invest. Dec 3 2012;122(12):4473-4489 
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1.9 HERV-K and melanoma 
Since the 1970s numerous reports have suggested the involvement of retrovirus like particles 
(RVLPs) in melanoma using electron microscopy and biochemical techniques (42). These 
RVLPs were initially detected in the lymph node of metastatic patients and they resembled 
the C-type virions and RT activity 142.These RLVPs had a reverse transcriptase activity and 
sequence homology to HERV-K 108 Gag and Env protein but were defective in replicating 
themselves and were noninfectious 143. In early 2000, studies reported that HERV-K antigen 
on tumor cells presented in the context of HLA-A2 and was detected by the patient CTLs 144. 
Pathology slide preparations of melanoma from various sites including lymph node and skin 
revealed the high copy number of HERV-K 108 via in situ hybridization. Absence of 
HERV-K 108 was observed in nevi tissues from healthy donors 143. Metastasis of melanoma 
was associated with the expression of full length HERV-K gag and env mRNA 145. Recently, 
antibody against HERV-K gag and env protein was detected in 16% of patient sera but not in 
normal controls. The serum HERV-K expression correlates with the reduced prognosis 
associated with melanoma disease progression 146.  
 
1.10 Targeting HERV-K during melanoma- Project overview 
  
We have shown that HERV-K env is specifically expressed in the 220 melanoma patient 
samples and absent in 33 normal donor organ tissues, each obtained from three different 
donors.  The antigen expression on the tumor cell surface at any point during cell culture was 
variable due to shedding of the env protein from the cell surface. This variation was detected 
by flow cytometry and pseudo-infection of HERV-Kneg EL4 cells. Over expression or 
knockdown of antigen was unstable and did not yield stable clones. Even though there was 
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no stable antigen expression on these EL4 cells by plasmid encoding HERV-K-env, we 
predict that the antigen should have a type 2 transmembrane protein structure in contrast to 
the suggested type 1 membrane based on the detection of both N and C terminal of the 
protein inside the cell. 
Our laboratory has previously designed a CD19-specific CAR for treatment of B-cell 
malignancies which is currently being evaluated in clinical trial 70,147. We electroporated 
PBMCs from a normal donor using a non-viral SB vector, and, the T cells expressing our 
CD19-specific CARs were selectively propagated on γ-irradiated artificial activating and 
propagating cells (AaPC) derived from K-562 cells 148, 149, 150. Based on this approach, we 
have successfully developed HERV-K-specific CAR+ T cells using the SB system and their 
numeric expansion on HERV-K+ AaPC. These CAR+T cells were also able to detect HERV-
K env shed from the tumor cell surface. In vivo, infusion of HERV-K env-specific CAR+ T 
cells decreased tumor burden in a mouse model of metastatic melanoma. These data suggest 
that ACT of HERV-K env-specific T cells are a potential therapeutic strategy for patients 
with melanoma.  
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Chapter 2:  Materials and Methods 
2.1 Study Design: The overall objective of this study is to determine the expression of 
HERV-K env on primary melanoma cells, but not on normal tissues, and to develop HERV-
K env-specific CAR+ T cells that can recognize and kill melanoma cells in vitro and in vivo 
expressing this TAA. The expression of HERV-K env was evaluated by IHC staining of 
patient samples and normal human tissue array using an H-index. The in vitro studies 
include construction of HERV-K env-specific CAR and evaluation of specificity and 
effector function (from multiple donors and tumor cells). Variability in tumor cell surface 
expression of HERV-K-env was apparently linked to shedding of this TAA, and, CAR+ T 
cells could recognize shed antigen. The efficacy of HERV-K env-specific CAR+ T cells was 
evaluated in a mouse model. All animal experiments were performed after the approval of 
Institutional Animal Care and Use Committee at MD Anderson Cancer Center (MDACC) in 
accordance to NIH guidelines for the Care and Use of Laboratory Animals. 
 
2.2 Immunohistochemistry: Tissue microarrays (catalog # ME1004a, ME2082b, FDA998t) 
obtained from U.S. Biomax (Rockville, MD) were hydrated with distilled water and antigen 
retrieval using citrate buffer pH 6 without EDTA was performed. Slides were blocked with 
3% hydrogen peroxide (Biocare Medical, Concord, CA), avidin (Biocare Medical), biotin 
(Biocare Medical) and polyclonal whole serum (Biocare Medical). Slides were incubated for 
30 minute each with HERV-K mAb (3 µg/mL) followed by biotinylated anti-mouse IgG 
(Biocare Medical) and strepavidin-HRP (Sigma-Aldrich, St Louis, MO) and visualized with 
a Mayer's Hematoxylin counterstain (Sigma-Aldrich). Similar staining procedure was 
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performed on the slides with isotype control mouse IgG2a (3 µg/mL) antibody (BD 
Pharmingen, Franklin Lakes, NJ). Percentage of HERV-K env antigen staining and 
expression intensity was quantitated using microscopy and pathology analysis. H-index was 
calculated as a product of intensity and percentage of HERV-K env expression on tumor 
tissue.  
 
2.3 Real-time polymerase chain reaction: Quantitative examination of HERV-K mRNA 
levels in normal tissue cDNA was performed using the StepOnePlus real-time PCR system 
(Applied Biosystems, Grand Island, NY). Pooled complementary DNA (cDNA; catalog # 
636742, 636743) from three different normal donors for each of the 16 different organs 
analyzed (Clonetech, Mountain View, CA). Five-fold serial dilution of normal donor tissue 
cDNA was performed to develop standard curves. For TaqMan assay primers (forward 
primer: 5-GGGTACCTGGCCCCATAGAT-3; reverse primer: 3-
CATCATCCCTTCTTCCTCAGGTT-5) and probes (5-ATCGCTGCCCTGCC-3) were 
obtained from Applied Biosystems. Reaction mixture (20 µL) containing 1 µL of cDNA 
template, 2 µL each of primer and probe mix, 10 µL TaqMan universal PCR master mix 
(Applies Biosystems) and water. Amplified was performed as follows: denaturation at 95°C 
for 10 minutes and 40 cycles at 95°C for 15 seconds, 60°C for 1 minute. Direct detection of 
PCR products monitored by measuring the fluorescence produced by the result of TaqMan 
probe hydrolysis after every cycle. Amplification efficiencies were tested for HERV-K env 
and housekeeping gene (RNaseP). All samples were tested with the reference gene RNaseP 
for data normalization to correct for variations in cDNA quality and quantity. All samples 
were performed in triplicate. The parameter threshold cycle (Ct) defined as the cycle number 
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at which the first detectable fluorescence increase above the threshold observed. For fold-
changes in relative gene expression was calculated using the equation ∆Ct = Ct (HERV-K 
env) − Ct (RNaseP). The ∆∆Ct is then calculated using ∆Ct values of HERV-K env+ K-562 
parental cell as reference using the equation, ∆∆Ct= ∆Ct (Normal organ) − ∆Ct (K-562). 
The relative mRNA expression is then calculated using the equation, relative mRNA 
expression = 2- ∆∆Ct 
 
2.4 Plasmids: The scFv sequence (from mAb clone 6H5) against HERV-K env protein (Dr. 
Wang-Johanning, MDACC) was codon optimized (CoOp) (Invitrogen, Carlsbad, CA) and 
cloned into SB transposon vector under human elongation factor-1α (hEF-1α) promoter, 
flanked by SB inverted repeats forming CoOp 6H5CD28/pSBSO. HERV-K env was cloned 
and expressed from SB plasmid containing bidirectional hEF-1α and cytomegalovirus 
(CMV) promoters. The codon optimized (CoOp) full length HERV-K env antigen sequence 
with the viral transmembrane domain was cloned under hEF-1α promoter and neomycin 
gene was transcribed under CMV promoter in a bi-directional vector, HERV-K (CoOp) 
Neo/pSBSO-Bidirectional. The transposase (SB11) was expressed in cis from the plasmid 
pCMV-SB11 151. The 6H5 CAR maxibody specific for the scFv derived from the 6H5 
antibody was fused to IgG4Fc domain and poly histidine tag and cloned into lentiviral vector 
PDC415 under SV40 promoter (Figure. 11) and expressed on HEK293 mammalian cells, 
and the supernatant was collected and purified using polyA columns (Fabion, Seattle, WA). 
To generate the in vivo imaging SB plasmid for T cells, codon optimized firefly luciferase 
gene was fused to myc tag under control of a CMV promoter. A lentiviral vector encoding 
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mKate-Renilla luciferase constructed under eEF1α promoter was used as an imaging vector 
for melanoma tumor cells in vivo.  
To understand the structure of HERV-K env, two different lentiviral plasmids were 
constructed modifying the HERV-K env signal peptide and transmembrane sequences. The 
signal peptide was either switched to IgKL sequence or modified to express FlagM2 and 
FlagM1 on either side of it. The transmembrane domain was switched to Fc-CD8. In both 
the plasmids, the furin cleavage site between the SU and TM domain was removed and 
protein was encoded under a RSV U3 promoter sequence and has a polyhistidine tag and 
mKate flourescence marker following the transmembrane domain for detection. 
 
2.5 Cell lines and their propagation: A375, A624, and A888 were provided by Dr. Laszlo 
Radvanyi (MDACC); EL4 parental cell line was obtained from American Type Culture 
Collection (catalog # TIB-39, Rockville, MD); and A375-SM (super-metastatic melanoma 
cell line) was received from the Characterized Cell Line Core Facility (CCCF) at MDACC. 
All cell lines were cultured in RPMI (Thermo Scientific, Rockford, IL) with 10% FBS 
(Thermo Scientific) and 5% glutamax (Gibco Life technologies, Grand Island, NY). All cell 
lines were verified by morphology, cell single tandem repeat finger printing and/or flow 
cytometry. They were routinely tested for Mycoplasma and all tests were negative.  
 
2.6 Generation and expansion of HERV-K env-specific CAR+ T cells: Generation and 
expansion of HERV-K env-specific CAR+ T cells were performed using a protocol 
previously described 149. Briefly, the 2x107 PBMC cells were washed and rested in complete 
RPMI supplemented with 10% fetal bovine serum (Thermo Scientific) and 1% glutamax 
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(Gibco Life technologies) for 2 hrs. On day 0, these cells were then re-suspended in 100 µL 
of Nucleofector solution (Human T-cell Kit) (Lonza, Allendale, NJ), with supercoiled DNA 
coding for HERV-K env-specific CAR transposon (15 µg
 CoOp6H5CARCD28/pSBSO) and 
supercoiled DNA coding for SB transposase (5 µg pCMV-SB11), transferred to a single 
cuvette, and electroporated using the U-14 program (Lonza). The electroporated T cells were 
rested for 4 hours at 37°C in complete phenol red-free RPMI (Thermo Scientific) after which 
a half-media change was performed. The K562-derived clone 4 expresses endogenous 
HERV-K env (Figure 11) and thus serves as AaPC to propagate HERV-K env-specific 
CAR+ T cells. The electroporated T cells cultured in RPMI containing 10% FBS were 
supplemented with γ-irradiated (100 Gy) K562-AaPC at a 1:2 T cell/AaPC ratio on day 1. 
Irradiated AaPC were re-added at the end of every week for T-cell stimulation at the same 
ratio. Soluble recombinant IL-21 (eBioscience, San Diego, CA) and IL-2 (Invitrogen) 
cytokines were supplemented at a concentration of 30 ng/mL and 50 U/mL respectively to 
complete RPMI media on a Monday, Wednesday, Friday schedule. Mock transfected 
negative “no DNA” control T cells were propagated in the presence of OKT3-loaded AaPC, 
IL-2, and IL-21. CD19-specific CAR+ T cells electroporated with CoOp 
CD19CARCD28/pSBSO and SB11 transposase and propagated under the same culture 
conditions as for HERV-K env-specific CAR+ T cells served as a negative control. The T-
cell cultures were monitored weekly for the contaminating presence of CD3negCD56+ NK 
cells which were depleted if this population exceeded 10% of the total population. A 
depletion usually occurred between 10 and 14 days of initial co-culture with AaPC and was 
carried out using CD56 beads (Miltenyi Biotech Inc, Auburn, CA) on autoMACS (Miltenyi 
Biotech) using the positive selection “possel” program according to manufacturer’s 
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instruction. T-cell viability was assessed by trypan blue exclusion using a Cellometer 
automated cell counter (Auto T4 Cell Counter, Nexcelom Bioscience, Lawrence, MA). The 
fold expansion was calculated (compared to day 1) of total, CD3+, CD4+, CD8+, and CAR+ 
cells at the end of 7, 14, 28, and 32 days of co-culture on AaPC with cytokines. The average 
CAR+ T-cell growth of 4 donors was compared between the CD19-specific CAR+ T cells 
and no DNA control cells using a Student’s t-test.  
 
2.7 Generation of HERV-K env-specific CAR+ ffLuc+ T cells by double transposition: 
Two SB plasmids encoding (i) HERV-K env-specific CAR and (ii) myc-ffLuc-neomycin 
(7.5 µg each) along with SB transposase (5 µg pCMV-SB11) were electrotransferred into 
PBMC and propagated on AaPC similar to HERV-K env-specific CAR+ T cells. A cytocidal 
concentration of neomycin (0.8 mg/mL) was added to select CAR+ffLuc+ T cells. All T-cell 
cultures received IL-21 (30 ng/mL) and IL-2 (50 U/mL) three times a week. 
 
2.8 Flow cytometry: One million cells were stained with antibody conjugated with 
fluorescein isothiocyanate (FITC), phycoerythrin (PE), peridinin chlorophyll protein 
conjugated to cyanine dye (PerCPCy5.5), or allophycocyanin (APC). All antibodies used are 
listed in (Supplement Table 1). Blocking of nonspecific antibody binding was achieved 
with goat IgG and using FACS wash buffer (2% FBS and 0.1% Sodium Azide in PBS). Data 
acquisition was on a FACS Calibur (BD Biosciences) using CellQuest version 3.3 (BD 
Biosciences). Analyses and calculation of median fluorescence intensity (MFI) was 
undertaken using FlowJo version 7.5.5.  
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2.9 Integration Analysis: Genomic DNA from HERV-K env-specific CAR+ T cells was 
isolated using a QIAamp DNA mini kit (Qiagen) and real-time PCR was performed as 
previously described 152. Genomic DNA from Jurkat cells (clone 12) bearing a single 
integration of the CD19-specific CAR copy previously described was used as a positive 
control.  The experiment was undertaken in triplicate with 100 ng of genomic DNA mixed 
with 10 µL of TaqMan Gene Expression Master Mix (Applied Biosystems, Foster City, CA), 
1 µL (1x probe at 250 nM and 1x primer at 900 nM) of 20x FAM labeled CAR-specific 
TaqMan probe primer set specific for IgG4Fc [forward (5’- 
GAGGGCAACGTCTTTAGCTG-3’) and reverse (5’-GATGATGAAGGCCACTGTCA-3’) 
primers and carboxyfluorescein (FAM)-labeled probe (5’-AGATGTTCTGGGTGCTGGTC-
3’)] and 1 µL (1x primer at 900 nM and 1x probe at 250 nM) of 20x VIC labeled TaqMan 
RNaseP Probe Primer set (Applied Biosystems) in a total reaction volume of 20 µL. The 
primers hybridize at the IgGFc4 portion of the CAR. Amplification cycle included: 2 
minutes at 50°C, 10 minutes at 95°C, forty 15-second cycles at 95°C, and 1 minute at 60°C 
and detection was performed with a StepOnePlus Real-Time PCR System (Applied 
Biosystems). Autosomal RNaseP gene present at 2 copies per diploid cell, was used as an 
endogenous reference for normalization. The
 
∆∆CT method (Applied Biosystems, CA) was 
used to calculate the number of integrations with reference to RNaseP and Jurkat clone as 
normalization controls 152.  
 
2.10 nCounter analysis digital gene expression system: Digital gene expression analyses 
were performed as previously described 153. Differences in gene expression between HERV-
K env-specific CAR+ T cells and no DNA control T cells were evaluated using the nCounter 
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Analysis System (model no. NCT-SYST-120, NanoString Technologies) 153. Briefly, 104 
HERV-K env-specific CAR+ T cells or no DNA T cells were lysed in RNeasy lysis buffer 
(RLT; 5 µL, Qiagen, Gaithersburg, MD) and the mRNAs were hybridized for 12 hours at 
65°C with a reporter probe code set and a capture probe code set (Appendix Table 2) 
custom designed using the nCounter Gene Expression Assay Kit. An nCounter prep station 
was used for the post-hybridization processes. R-program, tree-view and clustal view were 
used to output the data with statistical analysis.  
 
2.11 6H5 mAx: In order to measure the HERV-K env expression on the tumor cell surface 
we developed a 6H5 mAx specific for the HERV-K env antigen. 6H5 mAx represents 
soluble CAR by swapping the CD28 and CD3ζ endodomain with a polyhistidine tag (Figure 
15A). This construct was inserted into a DNA plasmid coding for lentiviral vector (Figure 
15B) which was introduced into 293 METR cells (provided by Dr. Brian Rabinovich) using 
Lipofectamine 2000 (Life Technologies, Grand Island, NY), and conditioned supernatant 
was concentrated using 100 kDa cut-off centrifugal filter (catalog # UFC910024, EMD 
Millipore, Billerica, MA). The 6H5 mAx was then purified using a polyA column (Life 
Technologies) and analyzed on a SDS-PAGE gel to confirm purity.  
 
2.12 ELISA: To determine the specificity of 6H5 mAx made, we coated the 96-well plates 
(NUNC) with purified HERV-K env recombinant protein K10 (from Dr. Wang-Johanning) 
at 0 to 1 µg/well as serially diluted in PBS buffer. Antigen-coated wells were incubated for 1 
hour at 37oC followed by washing with PBS containing 0.1% tween (PBST). 10% BSA was 
used for blocking nonspecific binding for 2 hours at room temperature. 6H5 mAx or 6H5 
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mAb or unrelated CD19-specifdic antibody (catalog # FMC63, Millipore) was added at 0.25 
mg/mL final concentration and incubated for 1 hour at room temperature. In some instances, 
10 mg/mL of blocking antibody (either 6H5 mAb or 6H5 mAx) was used followed by 
washing with PBST buffer and addition of probing antibody (6H5 mAx or 6H5 mAb). A 
secondary HRP-labeled goat anti mouse- (Pierce, Thermo Scientific) was used to detect 6H5 
mAb or unrelated CD19 antibody and HRP-labeled goat anti human (Jackson Laboratories) 
was used to detect 6H5 max. After the final washing 100 µL of tetramethyl benzidine ELISA 
substrate (Sigma-Aldrich) was added and incubated for 5 minutes in the dark. 50 µL of 1N 
sulfuric acid was then added to stop the reaction. The absorbance was measured at 450 nm 
using a plate reader Victor X5 (Perkin Elmer, Waltham, MA).  
2.13 sh-RNA mediated HERVK knockdown in A888-mel cells: HERV-K specific sh-
RNA and scrambled sh-RNA lentiparticles were kindly provided by Dr. Wang-Johanning 
(MDACC, Bastrop, TX). The A888 cells were grown to 90% confluence in a 6-well plate. 
The media was later replaced using optimum media with sh-RNA lentivirus (titre of 100 µl ) 
and polybrene (5 µg/ml) and transduced for 4 hours at 37oC and then replaced with regular 
RPMI media. The cells were then sorted based on GFP expression and grown further. 
Scrambled shRNA transduced A888 cells were used as control.  
2.14 Chromium release assay (CRA): The CRA was performed as previously described 
149,154
. Briefly, HERV-K+ targets were loaded with 51Cr for 2 hours and incubated with 
HERV-K env-specific CAR+ T cells or no DNA control T cells grown for 35 days and the 
percentage 51Cr release was calculated using the following formula:  
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2.15 Video time-lapse microscopy (VTLM): Tumor cells were co-cultured with HERV-K 
env-specific CAR+ T cells in Hi-Q4 glass bottom dishes (Ibidi, Verona, WI) with complete 
RPMI containing 1 ng/mL SYTOX (Invitrogen). Tumor cell death was recorded as the time 
when the tumor cell membrane was permeabilized and the cells produced green fluorescence 
using a BiostationIM cell-S1-P system (Nikon, Melville, NY). The camera captured at 7 
frames/min. The intensity of fluorescence in each tumor cell was recorded using live cell 
imaging software (Nikon) over a period of 15 hours. 
 
2.16 Intracellular IFN-γ assay: HERV-K env-specific CAR+ T cells were co-cultured with 
tumor cells at 10: 1 ratio in a round bottom 96 well plate with 200 µL of complete RPMI 
culture medium. Protein transport inhibitor (BD Golgi Plug containing Brefeldin A) was 
added to trap IFN-γ inside the cell. The co-culture was incubated for 4 hours at 37°C and 
then stained for HERV-K env-specific CAR expression for 20 minutes at 4°C. The cells 
were then washed, fixed, and permeabilized with 100 µL of Cytofix/Cytoperm buffer 
(catalog # 555028, BD Biosciences) for 20 minutes at 4°C. The permeabilized cells were 
then stained for the cytokine with anti-IFN-γ APC conjugated mAb. The cells were washed 
and analyzed by FACSCalibur (BD Biosciences). PMA (phorbol 12 myristate 13 acetate) 
and ionomycin (BD Biosciences) treated T cells were used as positive control. A similar 
assay was performed with no DNA control T cells. 
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2.17 Immunoprecipitation:  10 billion cells were grown and lysed using RIPA buffer 
containing protease inhibitor (Roche Applied Science, San Francisco, CA) and pre-cleared 
overnight with protein A beads at 4°C.  The beads were then removed and the supernatant 
was incubated for 3 hours with HA-tag antibody at 4°C. At the end of incubation, 40 µl of 
protein A beads were added and incubated again for 1 hour at 4°C. The beads were then spun 
down at very low speed for 1 minute and washed two times with cold PBS. These beads with 
the antibody-antigen complex were boiled with SDS and ran on 4-20% SDS PAGE. The gel 
was stained with commasie blue and submitted for mass spectrometric analysis.  
 
2.18 Confocal microscopy:  Ten million cells were stained for intracellular expression of 
HERV-K env using 6h5 mAx and IgG4 Fc-FITC antibodies. The cell membrane was 
perforated using Cytofix/Cytoperm buffer for 20 minutes at 4°C followed by a 30 minutes 
block with goat IgG. The cells were spun on to the positive side of a microscope slide at 
1000g for 1 minute. The stained sample was then visualized using OMX microscope 
(Applied Biosystems) using an oil immersion 100X/1.4NA objective lens magnification.   
The images were captured as z-stacks spanning 12 µm of the cell above and below the mid-
point using Photometrics EMCCD.  
 
2.19 Concentration of HERV-K env from conditioned tumor cell culture supernatant: 
10 million cells were plated in two T-75 flasks (if adherent) or one T-75 (if cells are in 
suspension) in RPMI media without FBS or glutamax for 32 hours. The supernatant was 
then harvested and passed through a 0.45 µm cell filter to remove debris and concentrated at 
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1000g for 10 minutes using 100 kDa cutoff centrifugation filter (EMD Millipore, Billerica, 
MA).   
 
2.20 Spinfection: 150 µL of concentrated tumor cell culture supernatant was plated with 106 
EL4 parental cells in a 48 well plate. The plate was then subjected to centrifugation at 1000g 
for 90 minutes at room temperature.  
2.21 Western blot analysis: All immunoblot assays were performed with 6H5 mAb instead 
of 6H5 mAx since the latter could not recognize denatured antigen. Ten million tumor cells 
were lysed with RIPA buffer containing protease inhibitor (Roche Applied Science, San 
Francisco, CA). Alternatively, concentrated cell culture supernatant from A888, A375, 
A375-SM, AaPC, and EL4 was also performed. Bicinchoninic acid assay (BCA) was used to 
detect protein concentration (Thermo Scientific Pierce). A 4 to 20% gradient gel (Biorad, 
Hercules, CA) was used to analyze 10 µg of protein boiled in 1X SDS-sample loading buffer 
(Bio-Rad). The protein was then transferred to a nitrocellulose membrane and blocked with 
5% non-fat dry milk in phosphate buffered saline with 0.1% tween 20 and incubated with 
6H5 HERV-K antibody (1 mg/mL). Binding was detected by goat anti-mouse Fc-HRP 
(catalog # 170-6516, Bio-Rad) and developed using ECL West femto substrate (Thermo 
Scientific Pierce). The blot was imaged using Versa doc Quantity one software (Bio-Rad).  
 
2.22 In vivo CAR+ T cell and tumor cell activity measurement by photon quantification:  
5 week old female NOD.Cg-PrkdcscidIl2rgtm1wjl/SzJ (NSG,  Jackson Laboratories, Bar 
Harbor, ME) mice were intravenously injected with 106 A375-SM-RmK cells on Day 0 155. 
Mice in the treatment cohorts (n = 7) received 2x107 HERV-K env-specific CAR+ ffLuc+ T 
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cells on Days 7, 14 and 21. 6x104 U IL-2 (eBioscience) was injected intraperitonealy (IP) on 
day of each T-cell infusion and twice on the day after. One cohort of mice (n = 6) bearing the 
tumor received no treatment while a control group of mice (n = 5) without tumor received a 
similar number of CAR+ T cells as in treatment group. Bio luminescence imaging (BLI) on 
mice in anterior-posterior position was performed weekly using a Xeno IVIS 100 series 
system (Caliper Life Sciences, Alameda, CA) to reveal the distribution and quantity of tumor 
and T cells as previously described 156. Mice were anesthetized and placed in for BLI. To 
measure the HERV-K env-specific CAR+ffLuc+ T-cell activity 150 µL (200 µg /mouse) of 
D-Luciferin potassium salt (Caliper Life Sciences) was injected IP. Ten minutes after 
injection emitted photons were quantified using the Living Image 2.50.1 (Caliper Life 
Sciences) program. To image the tumor cell activity 100 µL (60 µM final concentration) of 
EnduRen (Promega, Fitchburg, WA) was injected IP. 20 minutes after injection the tumor 
activity was quantified similar to ffLuc. Unpaired Student’s t-test was performed to establish 
statistical significance of the photon flux. The livers from the tumor alone and treatment 
groups were isolated on day 25 and imaged directly for mKate expression using a Leica 
M205FA stereo microscope and quantified for the number of metastatic foci present in each 
liver. 
 
2.23 Genetic modification of cell lines 
• HERV-K env+ EL4 cells: Two million mouse T cell lymphoma EL4 parental cells 
were suspended in the mouse T-cell nucleofector solution (catalog # VPA-1006, 
Lonza). HERV-K env-expressing SB transposon with bi-directional promoter and 
SB11 transposase (2 µg of supercoiled DNA) were added to a final volume of 100 
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µL which was transferred to a single cuvette and electroporated using the C-09 
program. The cells were rested for 4 hours at 37°C in electroporation media 
supplemented with 10% FBS (Thermo Scientific Pierce). The cells were then 
transferred to DMEM supplemented with 10% FBS (Thermo Scientific Pierce) and 
5% glutamax (Gibco Life technologies). Cells were cultured in the presence of 0.8 
mg/mL G418, and neomycin-resistant HERV-K env+ EL4 cells were sorted using 
HERV-K antibody. 
• HERV-K SU-Fc-CD8+ EL4 and IgKL HERV-K SU-Fc-CD8+ EL4:  One million 
EL4 cells in a 24-well plate were transduced with 100 µL HERV-K SU Fc-CD8 or 
IgKL HERV-K SU-Fc-CD8 lentiviral particles along with 5 mg/mL polybrene 
(Sigma-Aldrich). The plate was spun at 1000g for 90 minutes at room temperature 
and incubated for 4 hours at 37oC. The cells were grown in DMEM, 10% FBS 
(Thermo Scientific Pierce) and 5% glutamax (Gibco Life technologies). The cells 
were bulk sorted for 100% pure mKate+ population using a FACS cell sorter (BD 
Biosciences) to obtain a homogenous population. 
• A375-SM-RmK: One million A375-SM cells in a 24-well plate were transduced 
with 100 µL mKate-rRLuc lentiviral particles along with 5 mg/mL polybrene 
(Sigma-Aldrich). The plate was spun at 1000g for 90 minutes at room temperature 
and incubated for 4 hours at 37oC. The cells were grown in DMEM, 10% FBS 
(Thermo Scientific Pierce) and 5% glutamax (Gibco Life technologies). The cells 
were bulk sorted for 100% pure mKate+ population using a FACS cell sorter (BD 
Biosciences) to obtain a homogenous population.  
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Chapter 3:  Results 
3.1 Tumor-specific expression of HERV-K env on primary melanoma  
The 6H5 HERV-K env-specific monoclonal antibody (mAb) 157 was used in 
immunohistochemistry (IHC) to investigate expression of the HERV-K env protein. Initially, 
we evaluated melanoma tumor-cell lines A888, A624, A375, A375-super metastatic cells 
(SM) that are highly metastatic upon passage in mice 155, and K-562 parental cells. The 6H5 
mAb revealed the presence of full length HERV-K env represented as a single band on 
western blot at 66 kDa under reducing conditions which was absent in the mouse parental 
EL4 T-cell line (Figure. 6A) 157. This mAb was used to interrogate expression of HERV-K 
env on and in primary and metastatic melanoma and normal skin. Punctate cell surface 
expression (solid arrow) and diffuse cytoplasmic staining (dotted arrow) were observed in 
tumor cells in a mutually exclusive manner (Figure. 6B). IHC staining (scored from 0 to 3) 
was graded based on intensity of staining for HERV-K env (Figure. 6C). An H-index was 
calculated by multiplying the percentage of HERV-K env+ cells with the intensity of staining 
compared to the isotype control 158. The average H-index for melanoma was 9.2 (n = 220, 
standard error of mean (SEM) = 2.4) which was 206-fold greater (p <0.001) than normal 
skin (H-index = 0.045, n = 55, SEM = 0.03; Figure. 7A). The average H-index calculated 
for metastatic tissues (10.65, n = 84, SEM = 3.9) was greater than that for primary tissues 
(8.4, n = 136, SEM = 3.0) though this did not reach statistical significance (p = 0.07) 
(Figure. 8A). HERV-K env was observed on tumor cells originating from multiple 
anatomical sites (Figure. 8B). To determine whether HERV-K env expression was restricted 
to tumor cells, tissues from 33 types of healthy organs from three different donors were 
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assessed by IHC. Though we observed HERV-K env mRNA expression in normal human 
samples (cDNA pooled from three independent donors) (Figure. 9) we observed an apparent 
absence of HERV-K env expression on all of these normal tissues (Figure. 10). These data 
support our contention that HERV-K env is a TAA and that as it is expressed on the cell 
surface it may be targeted by HERV-K env-specific CAR+ T cells.  
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Figure. 6: (A) Immunoblot analysis of HERV-K env from K-562 parental, EL4 parental, 
A375, A375-SM, A624 and A888 cells. Actin protein expression was used as a control for 
protein loading. A representative blot from three independent assays is shown. (B) Tumor 
cells (400X) showing HERV-K expression on cell membrane (punctate pattern; solid arrow) 
or cytoplasmic staining (diffuse pattern; dotted arrow). C) Representative images of tumor 
cells (200X) with varying staining intensity (scored 0 to 3) of HERV-K env expression (top 
panel) when compared to isotype IgG2a control staining (bottom panel).  
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Figure. 7: (A) A dot plot representing H-index (measured as product of intensity of staining 
by percent HERV-K env+ tumor cells) of normal tissue (n = 55) and melanoma primary 
tumor samples (n = 220). Each dot in the dot plot represents an individual donor; unpaired 
Student’s t-test with Mann-Whitney post-test; ***p < 0.001. 
 
 
 
A 
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Figure. 8: (A) H-index of benign, primary and metastatic tumors. (B) H-index of patient-
derived malignant tissues are shown. Each symbol in the dot plot represents an individual 
donor; unpaired Student’s t-test was with Mann-Whitney post-test; ***p < 0.01. 
B 
A 
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Figure. 9: (A) RT- PCR bands representing mRNA expression of HERV-K env 108 in 
normal human tissues. (B) RT- PCR bands representing mRNA expression of 
housekeeping gene (G3PHD) in normal human cells. All experiments had (cDNA 
pooled from three independent donors and the experiment was repeated thrice.  
 
A 
B 
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Figure. 10: Representative pictures (200X) of HERV-K env antigen expression on tissues 
sections from 29 normal organs are seen. The H-index was calculated as zero since no 
staining was observed in these tissues. 
A 
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3.2 Generation and characterization of HERV-K env-specific CAR derived from 6H5 
mAb 
We engineered a CAR with specificity for HERV-K env based upon the VH (at 
amino terminus) and VL domains derived from the 6H5 mAb which were joined via Whitlow 
linker to form a single chain variable fragment (scFv). This was fused in frame to a modified 
human IgG4 hinge/Fc 159 stalk, CD28 transmembrane domain, and a combination of CD28 
and CD3ζ intracellular domains. This design is similar to our 2nd generation CD19-specific 
CAR (designated CD19RCD28) currently employed in clinical trials 149. We stably 
expressed this CAR on T cells derived from peripheral blood mononuclear cells (PBMC) 
using the SB transposon/transposase system (Figure. 11A). HERV-K env-specific CAR+ T 
cells were then selectively propagated on AaPC 160 (designated clone 4) derived from K-562 
cells which expresses endogenous HERV-K env and were previously genetically modified 
by lentivirus transduction to co-express CD64, CD86, CD137L, and a first-generation 
membrane-bound IL-15 (Figure. 11B) 149. Control T cells from PBMC were (i) mock 
electroporated without DNA (“no DNA control”) and expanded on AaPC clone 4 pre-loaded 
via transgenic CD64 with a CD3-specific mAb (OKT3) and (ii) CD19-specific CAR+ T cells 
generated per published method for our clinical trials 149. 95% of the 
electroporated/propagated T cells stably expressed the HERV-K env-specific CAR on their 
cell surface after 28 days of co-culture with AaPC in the presence of soluble recombinant IL-
2 and IL-21 (Figure. 12A). Compared with CD19-specific CAR+ T cells, no appreciable 
difference was seen in (a) growth kinetics of HERV-K env-specific CAR+ T cells (Figure. 
12B), (b) percentage outgrowth of CD3+CAR+ T cells (Figure. 12C), or (c) ratio of CD4 to 
CD8 T cells (Figure. 12D). The average copy number of integrated transposon was 1.6 (n = 
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3, standard deviation (SD) = 0.03) per T-cell genome (Figure. 13A) which is less than that 
reported after virus-mediated transduction of T cells to express a CAR 161. We evaluated the 
therapeutic potential of the T cells (n = 4) using multi-parameter flow cytometry which 
revealed the percentage of CAR+ T cells with naive (CD45ROnegCD45RA+CD28+; mean 
7.79 ± SD 2.3), central memory (CD45RO+CD45RAnegCD28+; 12.02 ± 10.4), effector 
memory (CD45RO+CD45RAnegCD28+; 87.9 ± 10.9) and effector memory RA phenotypes 
(CD45ROnegCD45RA+CD28+; 91.04 ± 3.4) (Figure. 13B). These effector memory T cells 
were further characterized as CD27+CCRneg (33.22% ± 24) similar to our previous reported 
data for CD19-specific CAR+ T cells (not shown) 162. We observed the outgrowth of 
granzyme-B+ HERV-K env-specific CAR+ T cells (98.17% ± 2.3, n = 4) suggesting that 
these cells should be cytotoxic (Figure. 13C). In addition to flow cytometry, we employed a 
set of 500 bar-coded probes to digitally count mRNA molecules to reveal selected gene 
expression. Compared to no DNA control T cells (n = 3), the HERV-K env-specific CAR+ T 
cells (n = 3) had significantly (p <0.5) increased levels of mRNA species coding for (a) 
chemokines and receptors (CCR1, CCR5, CCL3 and CCL4) 163, (b) transcriptional regulators 
(LRP5, PAX5, TCF7) (c) T-cell activators (CD80, RORA, KIR3DL2) and (d) genes 
participating in lysis (perforin1 and granzyme H) suggesting that the HERV-K env-specific 
CAR+ T cells are capable of producing an effective response against the target TAA (Figure. 
14). In aggregate, these data demonstrate that T cells could be modified with the SB system 
to express a CAR from 6H5 and propagated on HERV-K env+ AaPC generating a biologic 
product with therapeutic potential for melanoma. 
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Figure. 11: (A) Generation of HERV-K env-specific CAR+ T cells: (A) SB-derived DNA 
transposon (HERV-K CD28mZ (CoOp)/pSBSO) designed to express HERV-K env-specific 
CAR. Abbreviations: IR/DR: inverted repeat/direct repeat, hEF-1alpha/p: human elongation 
factor-1α hybrid promoter, HERV-K CD28mZ (CoOp): codon-optimzed HERV-K envelope 
scFv, ColE1: E. coli origin of replication, Kan/R: kanamycin resistance, Kan/p: kanamycin 
resistance promoter. PBMCs (n = 4) were electroporated with SB plasmids, HERV-K-
specific CAR and SB11 transposase and co-cultured with AaPCs with cytokines. (B) 
Schematic diagram representing propagation of HERV-K env-specific CAR+ T cells. 
A 
B 
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Figure. 12: (A) Representative flow plots of transient (day 1) and stable (day 28) CAR 
(binding of Fc-specific mAb) and CD3 expression on HERV-K env-specific CAR+ T-cell 
cultures. (B) Rate of expansion of total HERV-K env-specific CAR+ T cells and CD19-
specific CAR+ T cells propagated on aAPC and cytokines. There was no difference in the 
kinetics of expansion. (C) Rate of expansion of CD3+ and CAR+ HERV-K env-specific T 
cells propagated on aAPC and cytokines. (D) Average growth of CD4+ versus CD8+ HERV-
K env-specific CAR+ T cells is shown (n = 4). 
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Figure. 13: (A) Measurement of the copy number of CAR (transposon) in T-cell genome 
after electroporation and propagation. (B) Multiparameter flow cytometry to evaluate the 
phenotype of HERV-K env-specific CAR+ T cells. Each symbol represents an individual 
donor and the horizontal line represents the mean. (C) Venn diagram representing various 
subtypes of T cells using CD45RA, CD45RO and CD28. Representative flow plot (n = 4) of 
effector memory phenotype of CAR+ T cells on day 28 after electroporation and 
propagation. CAR+ T cells were co-stained with CD45RA, CD45RO and CD28 markers. 
Flow plot was analyzed for CD45RA and CD45RO and each subset was further gated and 
analyzed for CD28 expression. Data represented as mean ± SD (n = 3).  
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Figure. 14:  Digital gene expression analyses of HERV-K env-specific CAR+ T cells as 
compared to no DNA control cells. The intensity of green in the heat map reveals 0-3 fold 
increased gene expression while intensity of red reveals 0-3 fold reduction in expression of 
sets of genes ascribed to the cytokine, chemokine, transcriptional regulator and T-cell 
activator family. 
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3.3 Generation and characterization of HERV-K env-specific maxibody derived from 
6H5 mAb 
To help define the specificity of the CAR derived from 6H5, we generated a soluble 
version of this immunoreceptor as a maxibody (mAx) 164. The HERV-K env-specific 6H5 
mAx consisted of the 6H5 scFv (used to generate the CAR) fused to full-length human IgG4 
using the same modified hinge and Fc region employed in the CAR construct (Figure. 15A-
B). We evaluated cell-surface expression of HERV-K env on EL4, AaPC clone 4, A888, 
A375-SM and A624 cells using 6H5 mAb (Figure. 15C) and 6H5 mAx (Figure. 15D). 
There was a positive trend between the H-indices calculated using 6H5-derived mAb and 
mAx at three different time points (days 1, 2, and 3 after plating the cells on day 0; spearman 
correlation coefficient, ρ = 0.5, p = 0.06) (Figure. 16A) indicating that these two soluble 
species apparently recognize the same TAA. We also performed an ELISA and observed a 
comparable level of binding of 6H5-derived mAb and mAx to plate-bound purified 
recombinant HERV-K env antigen (designated K10) 157 (Figure. 16B). CD19-specific mAb 
and plate-bound CD19 antigen were used as a negative control (Figure. 16C). As both 
soluble reagents inhibit the binding of each other, the mAb and mAx thus appear to bind to a 
shared epitope on K10 (Figure. 16D). Taken together, the 6H5-derived mAb and mAx, 
appear to recognize HERV-K env lending support to the concept that the CAR expressed on 
T cells will also recognize this TAA in an antigen specific manner. 
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Figure. 15: Comparison of 6H5 mAb versus 6H5 mAx: (A) A representation of 6H5 
mAx. (B) Lentiviral plasmid encoding HERV-K env-specific 6H5 mAx. 
(PDC4156H5hIgG4pH) to co-express truncated HERV-K scFv and a polyhistidine tag for 
protein purification. Abbreviations: SV40: simian vacuolating virus 40 promoter, SV40 
small T Ag: SV40 small T antigen, SV 40 pA: SV40 polyadenylation signal, 6H5 VL: 6H5 
variable light chain, linker: Whitlow linker, 6H5 VH: variable heavy chain, Poly His: 
Polyhistidine, AmpR: ampillicin resistance domain. Histograms representing surface antigen 
expression of HERV-K env using (C) 6H5 mAb (black) and (D) 6H5 mAx (black). Isotype 
(grey) and secondary antibody (grey) were used as controls. 
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Figure. 16: (A) Correlation plot between tumor cell surface (A888, A624, A375, A375-SM, 
EL4) H-indices of 6H5 mAb or 6H5 mAx staining of tumor cells grown at three different 
time point with varying cell density (Spearman correlation coefficient ρ = 0.5033, p = 
0.067). (B) Binding of 6H5 mAx and 6H5 mAb to purified HERV-K env (K10) protein by 
ELISA. CD19 mAb was used as negative control. H-index was calculated as product of 
intensity of HERV-K env staining (MFI) on tumor cell surface and percent tumor cells 
positive for antigen expression. (C) ELISA showing the binding of CD19-specific mAb to 
CD19 and 6H5 mAb and 6H5 mAx not binding to CD19. (D) ELISA representing the 
binding of 6H5 mAx or 6H5 mAb to K10. Pre-incubation of K10 coated plate with 6H5 
mAx blocked 6H5 mAb binding and vice versa suggesting the epitope sharing between the 
two. IgG2a mAb was used as a negative control mAb. ELISA data represents mean ± SD 
from average of triplicate measurements that were pooled from two independent 
experiments. 
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3.4 Specificity of CAR+ T cells for HERV-K env 
The redirected effector function of CAR+ T cells was evaluated to establish specificity for 
HERV-K env. We modified HERV-K envneg EL4 cells to express HERV-K env (Figure. 
17A) to serve as targets (Figure. 17B). HERV-K env-specific CAR+ T cells specifically 
killed HERV-K env+ EL4, but not parental EL4 cells (Figure. 17C). To further test the 
specificity of the HERV-K-specific CAR, a lentivirus encoding HERV-K env-specific 
shRNA was transduced into A888 cells (to generate A888 knockdown KD) (Figure. 18A) 
Immunoblot analysis showed a decrease of approximately 50% HERV-K expression 
compared to a scrambled shRNA control (Fig4B). Using a CRA, we observed a 3 fold and 
2.7 fold decrease in killing of A888 and A888 transduced with scrambled shRNA compared 
to HERV-K transduced with HERV-K-specific shRNA, respectively. (p <0.05; HERV-K-
specific CAR+T cell effectors) (Figure. 18B). 
HERV-K env-specific CAR+ T cells also mediated lysis of melanoma cells expressing 
endogenous HERV-K env. Compared to control no DNA control T cells, killing of 
melanoma cell lines A888, A624, A375, A375-SM, which are recognized by 6H5, was 
significantly greater using HERV-K env-specific CAR+ T cells (p <0.001) (Figure. 19A). 
CD19-specific CAR+ T cells served as an additional negative control and failed to lyse A888 
and A624 tumor cells above background (Figure. 19B).  
Although the cell surface expression of HERV-K env varied at different time points 
during cell culture (days 1, 2, and 3 after plating the tumor cells on day 0) as assessed using 
6H5mAx by flow cytometry (Figure. 19C), we observed a positive correlation between lysis 
of melanoma cell lines by HERV-K env-specific CAR+ T cells and the density of HERV-K 
env expression on the tumor cell surfaces as calculated using H-index on (ρ = 0.68, p 
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<0.001) (Figure. 19D). We also examined the redirected lysis by HERV-K env-specific 
CAR+ T cells by video time-lapse microscopy (VTLM) 165,166. The genetically modified T 
cells were co-cultured with HERV-K env+ A888 or A375 tumor cells or HERV-K envneg 
HEK293 at an effector to target (E:T) ratio of 1:5. Twenty-five target cells were individually 
monitored from each cell line for 15 hours and the increase in fluorescence (associated with 
SYTOX in the media entering damaged tumor cells and intercalating with DNA) was 
calculated for A888 (mean fluorescent intensity (MFI) = 445, SD = 67.8), A375 (MFI = 434, 
SD = 20.6) which was significantly greater than HEK293 cells (MFI = 394, SD = 19.1) (p = 
0.016) (Figure. 20A-B). In addition to killing, we evaluated whether CAR+ T cells could be 
activated for IFN-γ production upon co-culture with melanoma cells. These tumor targets 
were co-cultured with HERV-K env-specific CAR+ T cells or CARneg no DNA control T 
cells at a 10:1 E:T ratio. Compared to control T cells, the percentage of IFN-γ+ HERV-K 
env-specific CAR+ T cells was 2.9, 5.1, 5.9, and 2.6 fold greater when incubated with A888, 
A375, A375-SM and A624, respectively (Figure. 21). These data reveal that CAR+ T cells 
are activated for killing and cytokine effector functions by HERV-K env.  
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Figure. 17: (A) A bidirectional Sleeping Beauty DNA transposon (HERV-K (coOp) 
Neo/pSBSO-Bidirectional) to co-express HERV-K env full length antigen and neomycin 
phosphotransferase (neo) for in vitro selection. Abbreviations: hEF-1alpha/p: human 
elongation factor-1α promoter, mCMV/p: mouse cytomegalovirus promoter, Neo/r: 
neomycin phosphotransferase. B) Representative flow plots (n = 3) of HERV-K env 
expression on EL4 cells transduced with HERV-K env antigen compared with HERV-K 
envneg EL4 parental. (C) A four hour CRA using HERV-K env-specific CAR+ T cells as 
effectors and either EL4 parental or HERV-K env+ EL4 cells as targets. 
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Figure. 18: (A) Immunoblot analysis of HERV-K env from A888 cells treated with HERV-
K env specific shRNA (middle lane) or scrambled shRNA (right lane). Actin protein used as 
a loading control. (B) CRA using HERV-K env-specific CAR+T cells as effectors and A888 
HERV-K env KD cells, A888 parental (A888P) and A888 scrambled cells as target. 
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Figure. 19: (A) A 4 hour CRA of HERV-K env-specific CAR+ T cells (solid line) compared 
to no DNA control T cells (dotted lines) using melanoma tumor cells as targets. (B) A four 
hour standard CRA (n = 3) using CD19-specific CAR+ T cells against CD19neg melanoma 
and CD19+ EL4 tumor targets. (C) Percentage expression of HERV-K env protein on tumor 
cell surface using 6H5 mAx. Each symbol represents a low (20%), medium (50%) and high 
(70%) confluence in the tissue culture flask (n = 3) and horizontal line the mean. (D) Plot of 
correlation between percent 51Cr release (effector: target ratio is 1:10) and H-index of tumor 
surface staining (A888, A624, A375) with 6H5 mAx ρ= 0.6895; p < 0.001).  
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Figure. 20: (A) Killing of tumor targets by HERV-K env-specific CAR+ T cells using 
VTLM. Targets were plated with CAR+ T cells for 15 hours at 1: 5 ratio in the presence of 
SYTOX. Representative images of 25 tumor cells from two independent experiments of 
HERV-K env+ cells (A888 and A375) or HERV-K envneg control (HEK293 parent) cells co-
cultured with CAR+ T cells at 0, 300, 600, and 900 minutes of VTLM. HERV-K env-
specific CAR+ T-cell interaction with HERV-K env+ tumor targets are indicated with two 
arrows at 300 minutes. Green fluorescence in tumor cells is indicated by two arrows at 600 
minutes consistent with cell death. (B) VTLM to assess killing by HERV-K env-specific 
CAR+ T cells and target cells in media with SYTOX. The intensity of the fluorescence was 
measured. Data represented as mean ± SD from 25 tumor cells pooled from two independent 
experiments.  
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Figure. 21: (A) IFN-γ production by CAR+ and CARneg T cells upon incubation with targets. 
Data represent mean ± SD from three healthy donors (average of triplicate measurements for 
each donor). Two way ANOVA with Bonferroni post-test was performed on CRA and IFN-γ 
production assay between the HERV-K env-specific CAR+ T cells and no DNA control cells 
*p < 0.05, **p < 0.01 and ***p < 0.001.  
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3.5 Characterization of HERV-K by structure:  
One of the hurdles faced during these specificity determination assays was that we could 
never stably over express or knock down the HERV-K env. The antigen expression on EL4 
HERV-K+ cells was lost within 10 days though the G418 resistance was retained. Antigen 
knockdown on A888 was detectable only intracellularly. Antigen expression also varied on 
the tumor cell surface at various time points. These factors led us to analyze the structure of 
HERV-K 108 env protein. A typical HERV-K env structure has a 13 amino acid long signal 
peptide, a surface domain, furin cleavage site and transmembrane domain (Figure. 22A) In 
contrast to previous publication 167, HERV-K seems to have a type II cell membrane protein 
structure (Figure. 22B) and the 13 amino acid long signal peptide does not have properties 
of a real signal peptide (Figure. 22C) when analyzed using the hydrophobic domain 
prediction and SignalP software.  Furthermore, we noticed the presence of a furin cleavage 
site between the surface and transmembrane unit which might cause unstable expression of 
HERV-K env antigen. Hence, we developed constructs with various modifications to the 
antigen which included removal of the furin cleavage site and replacing the transmembrane 
portion to a known Fc-CD8 transmembrane domain with IgKL as signal peptide (Figure. 
23A-C) or HERV-K env signal peptide domain flanked by flag M1 and flag M2 tags 
(Figure. 23B-C) in an attempt to stably express them on EL4 cells and understand the 
structure of the antigen. These changes yielded only transient but not stable expression of the 
surface envelope protein in contrast to Fc –CD8 transmembrane domain stably expressed 
intracellularly over a prolonged period of time detected by flow cytometry and mass 
spectrometry (Figure. 24A).  
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Immunoprecipitation of these cells after transient transfection (Figure. 25A) or stable 
transduction (Figure. 25B) of modified HERV-K env plasmids followed by mass 
spectrometry revealed the presence of the signal peptide and surface unit during transient 
transfection which is then lost during stable transduction while the Fc-CD8 is detected 
throughout the period of cell culture.  
Previous study has attributed the presence of cryptic cleavage sites for the inability to over-
express HERV-K env antigen on any cell surface 168. Un-biased mass spectrometric analysis 
performed without using any mAb–based pulled down on AaPCs and A888 cells (every 
single peptide on the cell membrane was documented) revealed the presence of other HERV-
K viral protein (pol and gag) along with other subtypes of HERVs including HERV-F, 
HERV-H and HERV-R in their total cell extract (Figure. 26A-B). These data suggest the 
presence of more than one type of HERV in a particular tumor cell. Our finding of punctate 
HERV-K expression on the cell surface of A888 cells is consistent with our hypothesis that 
HERV-K env is packaged as part of virions associated proteins which are required for stable 
expression at the cell membrane.  
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Figure. 22: (A) Schematic representation of HERV-K env 108 structure 167. (B) Published 
and predicted transmembrane hydrophobic domains. Grey bars and red peaks represent 
hydrophobicity. (C) Signal peptide prediction of HERV-K env signal peptide and IgKL 
signal peptide. Sharp peaks with IgKL represent strong correlation to signal peptide.  
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Figure. 23: (A) Modifications of HERV-K env signal peptide to IgKL and transmembrane 
domain to Fc-CD-HA (B) Modifications of HERV-K env signal peptide by flanking it with 
Flag M1 and FlagM2 on either side and switching transmembrane domain to Fc-CD-HA (C) 
Lentiviral plasmids encoding modified IgKl-FlagM1-HERV-K surface unit- Fc-CD8-HA 
and FlagM2-Signal peptide- Flag M1-HERV-K surface unit- Fc-CD8-HA. 
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Figure. 24: (A) Representative flowcytometry plots (n=3) of intracellular expression of 
HERV-K on day 1 and 15 and HA expression on day 15 on IgKL HERV-K SU-Fc CD8+ 
EL4 cells. 
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Figure. 25: (A) Peptide list from mass spectrometry analysis after transient transfection of 
FlagM2-Signal peptide- Flag M1-HERV-K surface unit- Fc-CD8-HA in EL4 cells. (B) 
Peptide list from mass spectrometry analysis after stable transduction of FlagM2-Signal 
peptide- Flag M1-HERV-K surface unit- Fc-CD8-HA in EL4 cells. Yellow highlights on the 
schematic HERV-K structure represents the position at which the peptides were retrieved.  
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Figure. 26: Unbiased mass spectrometrey analysis without used of mAb mediated 
immunoprecipitation (A) List of peptides retrieved from A888 total cell lysates that aligns to 
HERV protein (B)  List of peptides retrieved from AaPC total cell lysates that aligns to 
HERV proteins. 
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3.6 Expression of HERV-K on tumor cells: 
Since we could not stably express the antigen on HERV-K envneg cells, we wanted to better 
understand the HERV-K env activity in a tumor cell. We performed an intracellular staining 
on K-562 parental cells using 6H5 mAx and a FITC-conjugated secondary antibody. Images 
of the HERV-K env expression in the tumor cells were procured using an Applied Precision 
OMX deconvolution microscope. These high resolution images revealed five distinct 
patterns of staining independently seen in each tumor cell including (a) HERV-K env 
surrounding the nuclear membrane inside the cell, (b) diffuse staining all along the cell 
membrane and cytoplasm, (c) few punctate dots of HERV-K env mostly on cell membrane, 
(d) numerous punctate dots of HERV-K env mostly arranged towards one end of the cell and 
(e) rafts like structure dispersed on the surface of the cells (Figure 27. A-E). The punctate 
and diffuse staining seen here correlates to the staining seen on primary melanoma tumor 
tissues. These distinct patterns of staining also provide a clue that the HERV-K formed 
inside the cell moves outwards towards the cell membrane to form clusters that then fuse to 
form bigger raft-like clusters on the cell surface. These data correlated with the previous 
studies which predict that HERV-K env can be secreted from the cells from teratocarcinoma 
cell lines and breast cancer tumors.  
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Figure. 27: Volumetric nanoscope images of HERV-K env 
expression (using 6H5 mAx) on K-562 parental cells (A) 
HERV-K env found surrounding the nuclear membrane 
forming a ring shaped structure. (B) Diffuse staining in the 
cytoplasm of the cell. (C) Few punctate dots of HERV-K 
env intracellular and on cell surface. (D) Dense punctate 
staining found mostly on one side of the cell. (E) Raft-like 
structures found on tumor cell surface. 
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3.7 Shed HERV-K env when bound by tumor cells can be targeted by HERV-K env-
specific CAR+ T cells 
Since the percentage of HERV-K env expression appeared to vary at different time 
points when cultured tumor cells were analyzed by flow cytometry (Figure. 19C), we 
assessed whether cell-surface expression of this TAA was modulated as a result of shedding 
and re-attachment over time. Western blot analysis (under reducing condition) of the 
concentrated supernatant from culture of tumor cells (HERV-K env+ A375-SM, A375, 
A888, clone 4 and HERV-K envneg EL4 probed with 6H5 mAb revealed a single band at 55 
kDa consistent with cleaved HERV-K env lacking the transmembrane domain (in contrast to 
the 66 kDa band observed from the whole tumor cell lysates which includes the surface and 
the transmembrane domains) 169,170 (Figure. 28A). Pre-incubation of the 6H5 mAb with 
soluble K10 for one hour at 37 °C reduced the intensity of staining on the blot, supporting 
our contention that the band detected in the cultured supernatant was HERK-K env (Figure. 
28B). A similar band was not was observed in the flow through after concentrating 
conditioned supernatant through a 100 kDa filter suggesting that shed non-denatured HERV-
K env is more than 100 kDa in size (Figure. 28C). We next investigated whether shed 
HERV-K env could be used to introduce this TAA onto tumor cells. We collected 
conditioned supernatant from AaPC clone 4 since this cell line expressed a high level of 
HERV-K env by flow cytometry. The concentrated conditioned supernatant was spinfected 
with EL4 cells for 90 minutes 171. Negative controls consisted of concentrated tissue culture 
media in the absence of clone 4. We observed that the expression of transferred HERV-K 
env decreased over culture time from the cell surface after spinfection (Figure. 28D).  
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Since HERV-K env expression was unstable, shed into the surrounding tumor culture 
media and can be transferred to tumor cells through spinfection, we analyzed whether the 
transferred TAA could trigger a T-cell response.  IFN-γ production assay performed and 
HERV-K env-specific CAR+ T cells specifically produced high (13 fold) levels of IFN-
γ when co-cultured with EL4 cells after exposure to concentrated clone 4 supernatant, 
compared with control EL4 supernatant (media), or when control CD19-specific CAR+ T 
cells were used as effectors (p <0.001) (Figure. 29A). As a further control for the specificity 
of binding, we investigated whether concentrated media from A375-SM could block the 
ability of HERV-K env-specific CAR+ T cells to target A375-SM tumor cells. This 
conditioned supernatant, compared with media collected without exposure to tumor cells, 
resulted in a 20% reduction in tumor lysis (p <0.05) (Figure. 29B). These data indicate that 
HERV-K env protein is apparently present in the tumor cell supernatant and the shedding of 
the TAA may explain the variability of HERV-K env expression on the tumor cell surface 
during cell culture period. 
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Figure. 28: (A) Immunoblot (n = 3) revealing presence of HERV-K env in conditioned 
culture supernatant harvested from tumor cells. (B) Immunoblot assay (n = 3) shows 
specificity of 6H5 mAb by using recombinant protein (K10) to block binding to shed TAA. 
Conditioned supernatant from tumor cells containing shed HERV-K env protein was 
incubated with 6H5 and K10. (C) Immunoblot showing the absence of HERV-K env 
particles in the flow through after conditioned culture media was concentrated through a 100 
kDa membrane. (D) Representative flow plots (n = 3) using 6H5 mAx showing the ability of 
shed HERV-K env harvested from supernatant exposed to AaPC clone 4, to bind to cell 
surface of EL4 parental cells. 
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Figure. 29: (A) IFN-γ production (n = 3; mean ± SD) by HERV-K env-specific CAR+ T 
cells, but not control CD19-specific CAR+  T cells upon incubation with EL4 parental 
spinfected with conditioned or control EL4 media. (B) A 4 hour CRA (n = 3; effector: target 
is 1: 10) using HERV-K env-specific CAR+ T cells as effectors against A375-SM tumor 
targets incubated with concentrated A375-SM tumor supernatant. Concentrated RPMI media 
treated were used as control. Two-way ANOVA for IFN-γ production assay and one-way 
ANOVA for CRA with Turkey’s multiple comparison test was used *p < 0.05 and ***p < 
0.001.  
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3.8 Tumor-killing ability of HERV-K env-specific CAR+ T cells in vivo 
We investigated whether the anti-melanoma activity observed in vitro could be 
extended to an in vivo mouse model. T cells co-expressing Firefly luciferase (ffLuc) and 
HERV-K env-specific CAR were generated by “double transposition” using the SB system 
(Figure. 30A)  172. Metastatic melanoma A375-SM tumor cells 155 were genetically modified 
to co-express Renilla luciferase 8.6535 (rLuc) and mKate S158A fluorescent protein 173 from 
a bi-cistronic vector (A375-SM-RmK) (Figure. 30B). The growth kinetics, cytotoxicity, and 
specificity of HERV-K env-specific CAR+ffLuc+ T cells and HERV-K env-specific CAR+ T 
cells were not significantly different (p >0.05) (Figure. 31A and B). Next, we developed a 
xenogenic NSG mouse model of metastatic melanoma where A375-SM-RmK was 
intravenously (IV) injected (defined as day 0) (Figure. 32A). Following tumor cell 
engraftment in lung and liver, 2x107 HERV-K env-specific CAR+ffLuc+ T cells were IV 
administered with IL-2 (Figure. 32B). Bioluminescent imaging (BLI) was employed to 
serially measure rLuc-derived tumor burden on days 3, 10, 17 and 25. Localization of 
HERV-K env-specific CAR+ffLuc+ T cells was assessed the day after each T-cell injection. 
We observed that HERV-K env-specific CAR+ffLuc+ T cells co-localized with A375-SM-
RmK on days 7, 13, and 20 in the lungs (Figure. 32C). Twenty-five days after injection of 
tumor, we observed 4.7-fold increased rLuc activity in untreated tumor bearing mice 
compared to mice with tumor receiving HERV-K env-specific CAR+ffLuc+ T cells (p 
<0.001) (Figure. 32D). By this time point, the untreated mice had a hunch-back posture and 
appeared moribund. In contrast, mice treated with HERV-K env-specific CAR+ffLuc+ T cells 
were active and appeared healthy (Figure. 32E). The morphology of the liver in untreated 
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mice appeared shriveled and necrotic compared to the treated mice (Figure. 33A) and using 
optical imaging at necropsy a 75% reduction in fluorescent tumor colonies was observed in 
the livers of the T-cell treated group versus the untreated group (p <0.05) (Figure. 33B). The 
tumor cells both at the primary and metastatic sites (lung and liver) had increased HERV-K 
env expression compared to tumor cells with treatment on day 28 (Figure. 34A). Isotype 
control was used to compare the staining intensity between the tissues analyzed (Figure. 
34B). These data indicate that genetically modified CAR+ T cells can be used to treat mice 
with disseminated HERV-K env+. 
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Figure. 30: (A) A bidirectional Sleeping Beauty DNA transposon (HERV-K (coOp) 
Neo/pSBSO-Bidirectional) to co-express HERV-K env full length antigen and neomycin 
phosphotransferase (neo) for in vitro selection. Abbreviations: hEF-1alpha/p: human 
elongation factor-1α promoter, mCMV/p: mouse cytomegalovirus promoter, Neo/r: 
neomycin phosphotransferase. (B) Lentiviral DNA plasmid (PLV413G0RLUC8.6-535) was 
designed to co-express renilla luciferease 8.6535 and mKate 5158Amarker for in vivo and in 
vitro imaging. Abbreviations: Eo: RSV U3: Roes sarcoma virus U3 sequence, HIV R region: 
human immunodeficiency virus R region, HIV RRE: HIV-1 Rev response element, HIV 
cPPT: HIV central poly purine tract, RLuc8.6-535: renilla luciferase 8.6-535, mKate S158A: 
monomeric version of Katusha S158A, HBV PRE: Hepatitis B virus posttranscriptional 
regulatory element, HIV SIN LTR:  HIV self-inactivating LTR.  
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Figure. 31: (A) Inferred cell count (n = 3; mean ± SD) was plotted for HERV-K env-
specific CAR+ T cells and HERV-K env-specific CAR+ffLuc+ T cells. (B) A four hour CRA 
(n = 3; mean ± SD) revealing lysis of A375-SM versus EL4 parental cells with HERV-K 
env-specific CAR+ffLuc+ T cells. CRA data using 2-way ANOVA with Bonferroni post-test; 
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Figure. 32: (A) Schematic of in vivo experiment. (B) BLI images of rLuc-derived tumor cell 
activity in tumor group (n = 6) and treatment group (n = 7) mice from days 3 to 25. (C) Plot 
of average rLuc flux (mean ± SD) in treated (n = 7) and untreated (n = 6) mouse groups over 
time. (D) BLI images of HERV-K env-specific CAR+ffLuc+ T-cell activity in treatment 
group mice from days 7 to 30. (E) Survival plot of tumor (n = 6) and treatment group (n = 7) 
up to 30 days (p > 0.05). Statistics performed with two-way ANOVA with Bonferroni's post-
tests to calculate rLuc activity; Log-rank (Mantel-Cox) test for survival plot. **p < 0.01 and 
***p < 0.001.  
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Figure. 33: (A) Postmortem imaging of mKate-derived fluorescence representing melanoma 
metastatic foci in livers of treated and untreated mouse groups. (B) Bar graph of average 
number of tumor metastatic foci on treated and untreated mouse groups. Unpaired Student’s 
t-test was used to calculate significant difference in liver metastatic foci between treated and 
untreated mice *p < 0.05. 
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Figure 34: Immunohistological analysis of
 tumor with or without treatment with HERV
(A) Increased HERV-K env expression (shown in red) on lung and liver tissues 
bearing tumor alone compared to treatment 
(shown in red) on tumor on liver and lung tissues. 
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Chapter 4:  Discussion: 
HERV-K env has been incorporated in the human genome for millions of years. We have 
demonstrated its expression on tumor cells and primary patient tissues, including melanoma, 
but it is not expressed on normal tissues. We engineered a CAR specific for the HERV-K 
env which could be propagated on HERV-K env+ AaPCs and maintained a preferential 
effector memory phenotype. We have shown that the viral antigen is shed from tumor cell 
surface and could modulate the tumor microenvironment. HERV-K env-specific CAR+T 
cells specifically kill all HERV-K env+ tumor cells in an antigen-specific manner in vitro and 
diminish melanoma tumor growth and metastasis in vivo. 
 
HERV-K env has been reported to be expressed on the tumor cell surface of breast cancer, 
ovarian cancer, renal cell carcinoma, lymphoma, teratocarcinoma, prostate cancer, and 
infectious diseases such as AIDS 169,170,174-180. Various studies have been conducted to target 
HERV-K env antigen to develop novel treatment strategies. Some of the targeted therapy 
studies include development of 6H5 mAb against HERV-K env present on breast cancer 
cells which produced a ten-fold tumor volume decrease in a breast cancer mouse model 157. 
Renal carcinoma was precluded from formation and metastasis in mice with prophylactic 
vaccination targeted against HERV-K env 180. In vitro experiments on HERV-K env-specific 
CD8+ T cells obtained from patients with HIV responded to HIV infected cells resulting in 
eliminating these infectious cells in an HERV-K env antigen dependent manner 174. Anti 
retroviral drugs such as efavirenze and RNA interference (RNAi) against HERV-K 
decreased the tumor growth and metastatis of melanoma in a mouse model 181. HERV-K 
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env-specific TCR expressed on T cells lysed HERV-K+ melanoma tumor cells four-fold 
greater than HERV-Kneg melanoma cell line in vitro 144.  
 
 In this report, we demonstrated that HERV-K env is markedly up-regulated during the 
transition from melanocytes to primary and metastatic melanoma. Increased mRNA 
transcript levels of HERVK appear to be involved in melanoma progression resulting in 
morphological and cellular modifications such as diminished adherence capability and 
reduced level of HLA class I molecules or tumor cells associated with tumor progression 
182,183
.  In agreement with a positive correlation between HERV-K env expression and 
tumorgenicity, tissue-array analysis demonstrated increased levels of HERV-K expression 
from normal human tissue to tenfold greater in malignant melanoma. Multiple factors 
regulate HERV-K levels, for example  pro-inflammatory cytokines down regulate while 
steroids such as estradiol and progesterone are known to up regulate HERV-K env 
expression on tumor cells 184. Our IHC result has shown two distinct patterns of antigen 
expression: a diffuse cytoplasmic staining and a cell surface punctate staining. This punctate 
staining may be associated with recycle of HERV-K env in endosome between the 
cytoplasm and cell membrane and/or the budding off of exosome 178,185,186. This is consistent 
with the variability in cell surface expression for HERV-K env on tumor cell surface. Hence, 
HERV-K env is a more specific tumor associated antigen (compared to others such as 
HER2, CD19) that can be targeted on both primary and metastatic melanoma with limited 
off target toxicity.  
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In our attempt to understand the structure of the HERV-K viral envelope protein, we 
observed that with transient transfection, the antigen folds in a type II membrane based 
structure with the N-, C-terminal  and signal peptide being intracellular, and the surface unit 
of the envelop protein  detected partially on the cell surface. The presence of cryptic 
cleavage sites hinders any attempts to stably overexpress or knockout this antigen on cells 
168
. We performed un-biased mass spectrometric analysis on AaPCs and A888 mel cells, 
where the cell surface and intracellular proteins are biotinylated and every HERV-K protein 
biotinylated in the cell is detected. We found the presence of HERV-K pol and gag protein 
on the A888 cell extract along with HERV-F. The AaPCs on the other hand had HERV-K 
pol along with HERV-H and HERV-R proteins in their total cell extract. These data suggest 
the presence of more than one type of HERV in a particular tumor cell. The absence of 
HERV-K env but the presence of pol and gag is complimentary with our data in which we 
detect the presence of HERV-K env on tumor cell surpernatant. The ability of this viral env 
protein to be concentrated and infect HERV-Kneg EL4 cells temporarily and increase the 
IFN-γ production by HERV-K env-specific CAR+ T cells on exposure to these infected cells 
shows the potential of our therapy to prevent antigen escape. These mass spectrometry data 
also suggest that various HERVs could potentially work together but investigating it is out of 
the scope of this thesis. 
 
Being a highly immunogenic tumor, melanoma is an attractive tumor model for developing 
potent T cell based therapies. Favorable response was observed while targeting HERV-K 
antigen on melanoma cells using HERV-K env-specific TCR on cytotoxic T lymphocytes 
(CTLs) in vitro 144. A major limitation for TCR based T cell immunotherapy is HLA/antigen 
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restriction55. This reduces both antigen selection and the population size (HLA matched) 
which can be treated. Transgenic expression of scFv based CARs on T cells circumvents this 
restriction and confers non-HLA based antigen recognition 187. Genetic modification can be 
accomplished via viral or non-viral vectors. Our work using the SB system with 
electroporation is a non-viral approach that utilizes a transposon (encoding CAR) and 
transposon (responsible for genome integration). The main advantages of the SB system over 
viral transduction methods include (a) safety, (b) decreased integration into a 
transcriptionally active site (c) decreased cost and (d) yield of sufficient cells for clinical 
applications (>1 x1010) 152.  We were able to expand HERV-K env-specific CAR+T cells on 
AaPCs plus IL-2 and IL-21. Such numbers are known based on our preliminary clinical trial 
using CD19-specific CAR+T cells for the treatment of  B-lineage malignancies150. 50% of 
propagated HERV-K env-specific CAR+ T cells were grown of effector memory phenotype, 
previously shown to be more effective in vivo than other T cell phenotypes such as short 
lived effector T cells 188.   
 
It is important that the binding characteristics of the mAb from which a CAR is derived are 
maintained. We wondered, whether this was the case between the 6H5 mAb (mouse IgG2a) 
and the HERV-K-specific CAR. Thus, we generated a soluble recombinant maxibody 
version of the CAR consisting of the 6H5 scFv and human IgG4 Fc (6H5 mAx). Although 
both reagents bound to soluble HERV-K equally, we did observe some differential staining 
of melanoma tumor cell lines. Importantly, however, we observed a substantial correlation 
when the H-Index (product of percentage positive cells and MFI) for the mAb was plotted 
against that for the mAx. Although we only observed a subtle difference, it cannot be 
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assumed that a CAR engineered from a VH and VL chain of a given mAb will result in a 
CAR with similar binding characteristics. We strongly recommend that investigators 
engineer a mAx for each CAR designed and tested. It is conceivable that the HERV-K-
specific CAR recognize more than one member of the HERV family. To address this 
possibility, we performed western blot analysis for the 6H5 antigen using the lysates from 
several melanoma cell lines. In all cases, we only observed a single band at 66 KDa, the 
correct size of HERV-K 157, suggesting strongly that HERV-K-specific T cells preferentially 
and perhaps exclusively recognize HERV-K.  
 
HERV-K shed from spinfected cells over a short time duration describes the difference in the 
expression of HERV-K env antigen on tumor cell surface during culture period. Spinfection 
instead of ELISA was used to identify the expression of HERV-K env in the cell culture 
media of these tumor cells, since the latter technique could not detect the soluble HERV-K 
env antigen.  Initially a 100 kDa filter was used to concentrate the tumor cell culture media, 
but upon analysis using immunoblot technique a 50kDa band was seen. We predict the shed 
HERV-K env either appears an oligomer or associated with other proteins which gets 
dissociated when denatured and run on SDS-page. We could not attest to this prediction 
since immunoprecipitation of the shed antigen with either 6H5 mAb or 6H5 mAx did not 
yield any data indicating oligomerization or protein complexes due to high level of 
background noise. Various previous studies have demonstrated the capability of HERV-K 
env to extrude or bud from the tumor cell surface as immature provirus 167,189,190. This shed 
antigen was also detected in the plasma samples from patients with lymphoma and breast 
cancer. 169. Immature provirus can be made to infect normal cells by engineering artificial 
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mutations to remove the stop codons 191. The ability of this viral env protein to be 
concentrated and infect HERV-Kneg EL4 cells temporarily and increase the IFN−γ 
production by HERV-K-specific CAR+ T cells on exposure to these infected cells shows the 
potential of our therapy to prevent antigen escape. 
 
Though adoptive T cell therapy has been successful in reducing tumor burden in vivo, off-
target toxicity remains a primary concern. Other serious side effects include pulmonary 
therapy of T cells and subsequent cytokine storm that results in multi-organ failure. Such an 
event has occurred in a trial testing an ERBB2 specific CAR for the treatment of metastatic 
breast cancer 192. Liver toxicity can also occur. Five of eleven patients with renal carcinoma 
treated with carboxy anhydrase IX-specific CAR+T cells developed liver toxicity 193,194. 
Thus, for ACT to be successful the CAR should be specific and pulmonary/liver toxicity 
must be monitored diligently. We demonstrated that HERV-K env is indeed a highly specific 
TAA which can be targeted by HERV-K-specific CAR+T cells in vivo without causing 
pulmonary or liver toxicity.  
 
Hepatic metastatic melanoma is particularly difficult to treat and is associated with an 
overall median survival of only four months 195. The current standard of care includes 
chemotherapy, surgery, pro-inflammatory cytokine treatment and tumor antigen vaccines 
196,197
. All strategies are either ineffective, highly invasive or associated with serious side 
effects. In contrast, CAR-based T cell immunotherapies are advantageous for targeting 
tumors in hypervascular organ such as the lungs and liver. Using a mouse model of 
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metastatic model, a significant reduction in tumor growth and metastasis from lungs to liver 
was observed without known or observable adverse effects.  
 
Hence, targeting HERV-K env using adoptive T cell therapy may be a treatment option for 
multiple disease conditions. In conclusion, CAR based HERV-K env specific adoptive 
immunotherapy represents a promising treatment for multiple malignancies, which may 
circumvent many of the off-target effects observed in current clinical trials. 
 
4.2 Conclusion: 
 Advanced and relapsed melanoma is generally considered difficult to treat due to 
development of tumor resistance to conventional therapies. One way to extend patient 
survival will be to improve the host immune response to their tumor. To accomplish this, we 
have developed a strategy to infuse large numbers of tumor-specific T cells. Tumor-
specificity is achieved by modifying normal donor-derived T cells to express a receptor 
specific for a novel tumor molecule, envelope protein of human endogenous retrovirus-K 
(HERV-K env). This unique viral antigen was found integrated into the human genome and 
expressed selectively on melanoma cells and not on normal cells.  
 
For tumor-targeting, CAR specific for HERV-K env protein was genetically cloned into the 
T-cell surface using a non-viral sleeping beauty vector to integrate CAR into the T cells. 
These HERV-K env-specific CAR+ T cells were grown in an antigen specific manner to 
large numbers using our clinical grade AaPCs which endogenously express HERV-K env 
along with the required co-stimulatory molecules. We developed a solubilized version of the 
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HERV-K env-specific CAR called the 6H5 mAx and found a positive correlation between 
6H5 mAx and 6H5 mAb binding to HERV-K env antigen. HERV-K env-specific CAR+ T 
cells were found to target and lyse EL4 artificially engineered to express HERV-K env 
antigen and did not lyse A888 cells with HERV-K env knockdown using shRNA. These 
CAR+ T cells reduce the tumor load significantly by IFN-γ production and CAR-mediated 
lysis in vitro in an antigen dependent manner. 
 
 The antigen over expression was never stable possibly due to the presence of cryptic 
cleavage sites in the HERV-K env sequence. High resolution images of HERV-K env 
expression on tumor cell surface indicated that the tumor antigen is formed surrounding the 
nuclear membrane in the cytoplasm of the cell. The antigen then diffused in the cytoplasm or 
aggregated to form punctate structures which accumulated towards one part of the cell and 
later formed bigger rafts-like structure on the cell membrane. We later found that the HERV-
K env protein was shed from the tumor cell surface using spinfection technique. The shed 
HERV-K env antigen can be targeted by HERV-K env-specific CAR+ T cells specifically 
and elicit an immune response. Thus this therapy has the potential to avoid antigen escape 
due to shedding or becoming attached to other normal cells. In vivo, HERV-K env-specific 
CAR+ T cells were successful in reducing the tumor volume and decreasing metastasis of 
melanoma tumor cells.  
 
Thus, this therapy will benefit patients with aggressive and metastatic melanoma expressing 
HERV-K env antigen. While we have chosen melanoma as our tumor model, this study has 
the potential to be applied to other malignancies, including breast cancer, lymphoma and 
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myeloma due to the restricted expression of HERV-K env protein on these tumor cells. 
Benefits of this therapy include minimized off-target effects since normal tissue does not 
express HERV-K env and successful tumor clearance. This therapy can reduce the need for 
intense chemotherapeutic regimens with their concomitant toxicities.  
 
4.3 Future research:  
The mechanism which allows the presence of mRNA of HERV-K env but absence of the 
viral protein in normal cells needs to be researched. More work is required in understanding 
the role of these mRNA during normal cell function. Future research work is required to 
understand the role of other HERVs in tumor cells. Unbiased mass spectrometry showed the 
presence of other HERV viral proteins and it will be useful to learn the functional interplay 
between various HERV proteins and between various components of HERV-K virus during 
tumor progression. To better understand the structure of HERV-K viral env protein on the 
cell surface and the nature of its signal peptide better strategies of molecular cloning using 
cDNA library and mass spectrometry will be performed. Transmission electron microscopy 
will help us visualize the viral shedding dynamics from the tumor cell surface. Since the 
antigen is known to be shed from the tumor cell surface, tagging the virus with markers such 
as RFP and following its activity is under progress in order to better understand viral activity 
in a cell.  
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Table 2: List of target sequence used during mRNA analysis of HERV-K env-specific 
CAR+ T cells. 
 
 
 
 
 
 
 
 
 
 
107 
VITA 
Janani Krishnamurthy was born in Chennai, India on January 29, 1984, the daughter of Jaya 
Krishnamurthy and Krishnamurthy Rangarajan. After completing her work at Fatima High 
School, Chennai, India in 2001, she entered Sri Ramachandra Medical College (SRMC), 
Chennai, India. She received the degree of Bachelor of Pharmacy with a major in clinical 
Pharmacology and Pharmaceutics May, 2005. She then continued her education at 
University of Texas at San Antonio for next 2 years where she pursued her Master’s in 
Biotechonology with her thesis work on neuroimmunology. In May of 2008 she entered The 
University of Texas Health Science Center at Houston Graduate School of Biomedical 
Sciences.  
 
 
 
Permanent address : 
7900 Cambridge street, Apt 2-2F, 
 Houston Texas- 77054 
